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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a heritable renal disease that 
causes the enlargement of kidneys due to the bilateral development of fluid-filled cysts. This 
results in end-stage kidney disease in adults and a reduced life expectancy.  
 
While it is known that a mutation within a PKD-causing gene is required for the development 
of ADPKD, the underlying mechanisms causing cystogenesis and allowing the progression of 
disease are not well understood.  
 
As a result of this poor understanding there are few treatment options for patients with ADPKD, 
therefore a large proportion of patients will progress to end-stage renal disease for which they 
will need dialysis or renal transplantation. 
 
Epigenetic modifications including DNA methylation are known to be altered in neoplasia, for 
which there are now several FDA-approved therapeutic drugs. As there are many similarities 
between ADPKD and neoplasia, we postulate that like tumour tissue, ADPKD tissue contains 
differentially methylated regions that may be exploited for future therapeutic discovery. 
 
To investigate this, we have performed reduced representation bisulfite sequencing (RRBS) on 
four ADPKD kidney tissue samples, and three non-ADPKD kidney tissue samples. In this 
analysis we confirm that there are 13 regions in the genome with differential methylation, and 
there is a global trend of hypomethylation in ADPKD. Furthermore, the 3’ end of the 






To investigate whether DNA methylation changes are universally changed in ADPKD cysts, 
we performed RRBS on a further eight ADPKD samples, each from unique cysts from a single 
ADPKD patient. In this analysis there were differential methylation patterns in each cyst, 
however these changes were not consistent between cysts. 
 
These data show trends in global methylation in ADPKD not previously reported, and 
methylation changes within the genes NAGLU and GET4 concomitant with gene expression, 
which require further investigation to identify their role in ADPKD. 
 







ADPKD Autosomal Dominant Polycystic Kidney Disease 
ANOVA Analysis of Variance 
ARPKD Autosomal Recessive Polycystic Kidney Disease 
cAMP  Cyclic adenosine 3′,5′-monophosphate 
cDNA  Complementary DNA 
CKD  Chronic Kidney Disease 
CpG  Cytosine-Guanine dinucleotide 
Cq  Quantitation Cycle  
DMEM Dulbecco’s Modified Eagle Medium 
DMF  Differentially Methylated Fragment 
DNMT DNA Methyltransferase 
EDTA  Ethylenediaminetetraacetic Acid 
EGF  Epidermal Growth Factor 
ER  Endoplasmic Reticulum 
ESRD  End Stage Renal Disease 







FDA  Food and Drug Administration 
FDR  False Discovery Rate 
FFPE  Formalin-Fixed Paraffin-Embedded 
HAT  Histone Acetyltransferase 
HDAC  Histone Deacetylase 
LOH  Loss of Heterozygosity 
LTA  Lipoteichoic acid 
MCKD Medullary Cystic Kidney Disease 
MDCK Madin-Darby Canine Kidney 
miRNA Micro RNA 
mRNA  Messenger RNA 
mTOR  Mammalian Target of Rapamycin 
NBF  Neutral Buffered Formalin 
NF-𝜅B  Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells 
NPHP  Nephronopthisis 
OFG  Otago Genomics Facility 
PC1  Polycystin 1 






PCC  Pearson’s Correlation Coefficient 
PCR  Polymerase Chain Reaction 
PKD  Polycystic Kidney Disease 
PLD  Polycystic Liver Disease  
qPCR  Quantitative Polymerase Chain Reaction 
RC  R3277C 
RRBS  Reduced Representation Bisulfite Sequencing 
SV40  Simian Vacuolating Virus 40 
TAE  Tris-Acetate-EDTA 
TRPP2  Transient Receptor Protein 2 
TSA  Trichostatin A 
TSS  Transcription Start Site 
VPA  Valproic Acid 
Wnt  Wingless/Integrated 
WT 9-7 Wild Type Recombinant Adeno-SV40 Virus 9-7 Cell Line 
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common heritable renal 
disease in humans. Characterised by the development of large, fluid-filled cysts throughout 
both kidneys, this disease has an estimated prevalence of 3 in 10,000 [1]. As cysts continue to 
develop and grow throughout a patient’s lifetime, the kidney will ultimately enlarge from less 
than 200 g in a healthy person to upwards of 1.5 kg in some ADPKD patients. The amount of 
cystic growth (both by number and volume) varies between patients, from patients who develop 
only a few cysts and have adequate renal function in late adulthood [2], to patients with cysts 
visible as early as in utero, and who experience severe and rapidly progressive disease [3]. 
 
As a consequence of the growth of these cysts, renal function is impaired. It is assumed that 
either the destruction of the renal parenchyma [4], the fibrosis of interstitial kidney tissue [5], 
the disruption of the renal architecture [6, 7], or a combination of any of these precludes the 
regular function of nephrons [8]. Patients present with symptoms that reflect the decline of renal 
function, including flank pain, hypertension and various urinary complications. Interestingly, 
ADPKD patients experience several cardiac-related symptoms, and patients often develop 
hypertension ten years earlier than the average person (even when they exhibit adequate renal 
function). Common extrarenal symptoms include cysts in other organs such as the liver, 
pancreas and intestines. The prevalence of intracranial aneurysms is also higher in ADPKD 
patients than the general population [9, 10]. Many of these extrarenal symptoms are caused by 
connective tissue defects [11]. 
 




Associated with significant morbidity, the progression of ADPKD will ultimately inhibit renal 
function to the point of end-stage renal disease (ESRD), at which point patients may require 
dialysis or renal transplantation. An estimated 50% of ADPKD patients will reach ESRD by 
age 60 [12, 13]; in New Zealand ADPKD is the fourth most common reason for dialysis [14]. 
Despite the significant burden ADPKD can play on the medical system, there is currently no 
cure for the disease, and patients are treated with a limited number of therapeutics that show 
moderate improvement in some patients. One of the currently available therapeutic options is 
the vasopressin V2-receptor antagonist tolvaptan. Tolvaptan has been approved for the 
treatment of ADPKD in several countries, as it attenuates the rate of cyst growth by half, 
delaying the onset of ESRD. However, this drug has undesirable side effects including resulting 
in abnormal liver function tests, which results in poor patient tolerance [15]. Additionally, the 
efficacy of tolvaptan has been deemed insufficient for approval from the US Food and Drug 
Administration (FDA) [16]. As a result of these factors, ADPKD patients have a reduced life 
expectancy than that of the general population [12, 17]. 
 
1.1 The genetic background of ADPKD 
ADPKD is genetically heterogeneous – a germline mutation within a PKD-causing gene is a 
prerequisite for patients to develop this disease. PKD1 is the most prevalent disease-causing 
gene for ADPKD, with approximately 85% of patients having mutations within this gene. It 
was previously assumed PKD2 accounted for the remaining 15% of patients [18]; however, the 
sequencing of patients with atypical ADPKD has led to the discovery of patients with mutations 
in genes including GANAB [19] and DNAJB11 [20], which are now considered to be PKD-
causing genes for a small proportion of patients. Approximately 10% of patients have no family 





There is no mutation ‘hot-spot’ within these genes; over 1,800 mutations have been identified 
as contributing to the pathogenicity in ADPKD. These are highly variable, spread across each 
gene, and are typically unique within families. A database of ADPKD mutations within PKD1 
and PKD2 has been established (pkdb.mayo.edu) [22], with frameshift mutations accounting 
for the largest percentage of predicted pathogenic mutations recorded to date. The pattern of 
inheritance in ADPKD follows that of autosomal dominance, as most patients are heterozygotes 
for the pathogenic mutation they carry. 
 
Patients with a mutation within PKD1 are classed as type I ADPKD patients, while patients 
with a mutation within PKD2 are type II ADPKD patients. PKD1 mutations affect males and 
females equally, with a median onset of ESRD (or death) at 53 years. PKD2 mutations affect 
males and females differently, however, as males have an earlier median onset ESRD than 
females (67 and 71 years, respectively) [18]. There is insufficient data on the epidemiology of 
other pathogenic genes in ADPKD due to their recent characterisation and low prevalence.   
 
Features of the PKD1 gene (16p13.3) make it likely to be more susceptible to somatic mutation.  
It has a high GC content [23], which makes it more vulnerable to slippage errors during 
replication [24], and the presence of a long polypyrimidine tract within intron 21, which may 
predispose the gene to mutation [25]. PKD1 spans almost 50 kb of the genome, but it has an 






Figure 1.1: Features of the ADPKD-associated gene PKD1 
PKD1 is 50 kb in length and runs in the 3’ 5’ direction. Regulatory elements within the gene include 
multiple CpG islands, an area of H3K27Ac within intron 1, DNase clusters associated with the CpG 
islands and H3K27Ac region. There are also three miRNAs within the gene and promoter: miR-1225, 
miR-4516 and miR-3180-5. The 3’ end of TSC2 is directly adjacent to the 3’ end of PKD1. Image 
generated on the UCSC genome browser with the GRCh37/hg19 genome annotation. 
http:/genome.ucsc.edu [27, 28]. 
 
Alternative splicing of Pkd1 is observed in mouse and rat models [29, 30], however analysis of 
PKD1 is complicated due to the multiple pseudogenes, so it is unclear whether alternate splicing 
is present or plays a role in PKD1 expression.  There are also six pseudogenes ~13 Mb upstream 
of PKD1 which share a 97-99% homology with sequences from exons 1-33 [31, 32]. These 
may indicate a propensity for this region of the genome to experience somatic mutation; in 
cancer somatically acquired pseudogenes mirror features seen in retrotransposons [33]. 
 
Conversely, PKD2 (4q21) is a single copy gene. It spans 68 kb of the genome, with an ORF 
~5 kb [34]. Multiple alternative splicing transcripts have been identified in PKD2, including 
some which are not present in polysomal fractions, indicating that perhaps they play a role in 





For the purposes of this research, patients with assumed or confirmed type I ADPKD are 
investigated, and thus the discussion into ADPKD predominantly features type I ADPKD 
characteristics. 
 
1.2 PKD genes and Polycystins 
PKD1 encodes the protein polycystin-1 (PC1), a 462 kD integral membrane protein with both 
an extracellular and an intracellular terminus (Fig. 1.2). The extracellular N-terminus, which 
makes up approximately 75% of the protein, contains various domains capable of binding to a 
range of molecules including collagen, fibronectin, proteins and lipids. Of particular interest 
are the cell wall integrity and stress response component homology domain (which may bind 
to carbohydrates) and a C-type lectin domain for which carbohydrate binding is calcium-
dependent [31]. The intracellular C-terminus also interacts with lipids and proteins, although 
the function of this terminus appears to play a role in signalling, as this tail contains a G-protein-
activation site and phosphorylation signalling sites. Overall, PC1 has a structure indicative of a 






Figure 1.2: Structure of Polycystin 1 and Polycystin 2 
Polycystin 1 (left) is a 462 kD protein, predominantly comprised of an extracellular N terminus. This 
terminus contains a cytosine-flanked leucine repeat sequence (LR), which is capable of binding collagen, 
fibronectin and laminin; a cell wall integrity and stress response component domain (WSC); PKD1-like 
IgG-like repeats (IgG-like) which can bind protein ligands; and a C-type lectin which binds 
carbohydrates in a calcium-dependent manner. The intracellular C terminus contains a G-protein 
activation site, and a coiled-coil domain which has been postulated to assist with binding to the coiled-
coil domain of Polycystin 2. PC2 (right) is a smaller protein of 110 kD. The transmembrane domains 
share homology with the transmembrane domains of PC1, and the extracellular loop between domains 
5 and 6 forms a pore (which allows calcium to flow into the cell). The intracellular N terminus of PC2 
contains SH3 domains which allow the binding of focal adhesion proteins such as tensin. Adapted from 
Wilson (2004) [5]. 
 
Polycystin-2 (PC2) is a 110 kD protein (Fig. 1.2). The transmembrane domain of this protein 
shares a homologous region with a section of the transmembrane domain within PC1, however 
the proteins have different functions. The six transmembrane domains of PC2 form a pore, 
which acts as a nonselective cation channel capable of transporting Ca2+ [36]. PC2 belongs to 





It is believed that PC1 and PC2 form a polycystin complex together, which may have a 
mechanotransduction role in which the receptor molecules of PC1 influence the capacity of 
PC2 to transport Ca2+ [37]. 
 
1.3 Molecular characteristics of renal cysts in ADPKD 
ADPKD cysts demonstrate variable thickening of the basement membranes as well as 
alterations in the matrix composition [5, 12, 38]. Epithelial cells derived from ADPKD are more 
adherent to type I and IV collagen [39, 40]. The relationship between the cells and the matrix 
may also be influenced by abnormal numbers of integrin receptors. In mice, it has been 
demonstrated that the over-expression of matrix and focal adhesion complex-associated 
proteins such as tensin results in the growth of a high number of cysts [41, 42]. 
 
A key process during development is regulating the polarity of cells through the location of 
specific proteins in order for correct renal function to occur [43]. Tissue from ADPKD has 
altered polarity, including the relocation of the Na+/K+-ATPase pump from the basolateral to 
the apical cell membrane [44]. This suggests the ability to regulate polarity is lost (or never 
activated) in cystic tissue. Additionally, the isoform present in the cystic cell is the fetal form 
α1β2 rather than the mature isoform α1β1, suggesting that the fetal isoform is never 
downregulated in mature cells. Furthermore, polarity of PKD1 is also altered in ADPKD. While 
typically characterised as a membrane protein, PKD1 has been found primarily in the cytoplasm 
of ADPKD epithelial cells [45]. 
 
The ADPKD epithelia respond abnormally to signalling molecules. In the ADPKD kidney, 




epithelia to proliferate. In mice it has been demonstrated that inactivation of the apoptosis 
inhibitor bcl-2 is sufficient to cause renal cysts. 
 
Conversely, the proliferation of renal epithelia – which should cease at adulthood – continues 
in ADPKD. Epithelial cells originating from the ADPKD kidney have been proven to have an 
increased capacity for proliferation. ADPKD is also more susceptible to stimulation from the 
growth factor EGF, which is another cause of cystic proliferation. This can be demonstrated in 
transgenic mice overexpressing the receptor erb-b2, which develop focal dilation and 
proliferation of tubular epithelia [46]. 
 
EGF is secreted into the cystic lumen in quantities than can initiate proliferation. Combined 
with the abnormal location of EGF receptors in the luminal membrane, this mechanism 
contributes to the growth of cells. The inhibition of these receptors in mice reduces the number 
of cysts. Other growth factors, cytokines, lipid factors, ATP and cAMP all are present within 
the cyst fluid and contribute to the proliferative capabilities of the epithelia. 
 
The ADPKD-causing genes PKD1 and PKD2 have many purported roles in ADPKD. One such 
role involves a signalling cascade which leads to cell proliferation, migration and differentiation 
by repressing transcription factors such as TCF/LEF, AP-1 and STAT1. These genes control 
other pathways such as Wnt signalling. 
 
1.3.1 Characteristics of PKD1 in ADPKD 
Although it is known that a germline mutation to either PKD1 or PKD2 is typically required 
for ADPKD, the direct relationship these genes have with the onset of disease is not clear. It 




(either due to truncation or misaligned protein folding), thereby causing a loss of polycystin 
dosage, or function, sufficient to cause cystogenesis. 
 
Loss of polycystin dosage has been demonstrated in mice, where the knockout or reduction of 
Pkd1 is sufficient to cause cystic disease, as well as extrarenal manifestations typical of 
APDKD (Table 1.1). 
Table 1.1: Evidence demonstrates either an increase or decrease of PKD1 and Polycystin 1 causes 
ADPKD 
Mouse model section adapted from Happé and Peters (2014) [67]. 
 
However, the loss of dosage model is contrary to observational evidence in human ADPKD 
tissue. Various analyses of PKD1 expression in tissue derived from ADPKD cysts has shown 
evidence that PKD1 expression is increased in cystic tissue (Table 1.1). These analyses are not 
conclusive evidence that ADPKD is caused by the upregulation of PKD1, as a significant 
proportion of cyst (10-20%) are deemed to have an absence of the protein in some studies [6, 
63]. However, they do demonstrate that the relationship between PKD1 and ADPKD is not as 
simple as loss-of-function animal models previously described. 
 
Mouse models: Reduction of Pkd1 
Knockout mice [47-51] 
Conditional knockout mice [52-54] 
Inducible knockout mice [49, 55] 
Hypomorphic mice [56-59] 
Mouse models: 
Increased expression of (human) PKD1  [60, 61] 
Human tissue: 
Variable PKD1 expression in human tissue  [62] 
Human tissue: 




1.4 Cystogenesis in ADPKD 
Cysts initially arise from the proliferation of epithelial cells within a nephron tubule. The 
accepted model of cyst development is based upon focal proliferation (Fig. 1.3), where a single 
epithelial cell undergoes some form of genetic event, altering the function of the cell and 
initiating abnormal proliferation [4].  The resulting mass of cells then fills with fluid and will 
bud off from the nephron of origin to become an independent cyst. The monoclonal nature of 
ADPKD cysts has been demonstrated [68], supporting the concept that the origin of a cyst is 
likely from one epithelial cell. 
 
Figure 1.3: Focal proliferation as a model of cyst development 
Focal proliferation is widely agreed upon as the mechanism by which cysts develop. In this model, a 
genetic event generates cystic cells (red), which proliferate and expand out of the renal tubule, until they 
bud off and expand as a single, independent cyst. 
 
Cysts continue to grow, likely as a result of fluid intake and the continual cellular proliferation. 
Cyst growth as measured by total kidney volume is variable, and is calculated to increase at a 
rate of 1-10% per year [69, 70]. 
 
Although each kidney contains roughly one million nephrons [71] which all carry the germline 
PKD-causing mutation, less than 1% of these will develop into a cyst [72]. In this respect, 
ADPKD is dominant at the genetic level, but recessive at the cellular level. Therefore, it is not 
the germline mutation alone causing cystogenesis, but one or more additional molecular 




each PKD kidney in order for the characteristic cystic kidney to develop. A number of 
hypotheses have been suggested to explain the initiation of cystogenesis in ADPKD. 
 
1.4.1 Loss of heterozygosity 
In 1992 it was first proposed that ADPKD was caused by the loss of the second ‘wild-type’ 
copy of PKD1, comparable to the repression of tumour suppressor genes in heritable cancers 
[73].  This mechanism is dubbed the “two-hit hypothesis”, and there is experimental evidence 
to demonstrate that this does occur in some cysts from ADPKD patients. Multiple studies have 
identified loss of heterozygosity (LOH) in PKD1, in approximately 12-24% of selected 
ADPKD cysts, based upon microsatellite analysis. [68, 74, 75]. The true rate of LOH in 
ADPKD may be higher due to single nucleotide polymorphisms rather than the specific 
translocations tested in these studies, although it is unlikely to account for the development of 
all cysts. 
 
In the LOH model, the rate at which patients acquire a second hit plays a role in determining 
the course of disease. This would also explain the phenotypic variability between different 
patients. However, for this model to account for all cyst formation, there must be extremely 
high rates of somatic mutation within PKD1 and PKD2. In addition, while LOH is frequently 
cited as a theory to explain the mechanism underlying cystogenesis initiation, there are some 
experimental observations (such as increased gene expression, see Section 1.3.1) which LOH 





1.4.2 Incomplete penetrance 
Papers published in the late 2000s report the screening of PKD1 and PKD2 in consanguineous 
ADPKD families that do not fit the normal paradigm of single dominantly inherited mutations 
in ADPKD. 
 
A notable PKD1 mutation R3277C (RC) was found and determined to be the pathogenic 
mutation in a family. The RC allele appears to show a “low potency” where heterozygous 
family members show minimal disease and develop only a few renal cysts. This is unlike typical 
PKD1 mutations, where heterozygotes develop significant ADPKD. However, the homozygous 
family members with two copies of RC presented with severe ADPKD that progressed to ESRD 
and required transplantation [76]. In another family, the in utero onset of polycystic kidney 
disease was found to be the accumulation of the RC allele in trans with another, more severely 
pathogenic and completely penetrant PKD1 mutation [77]. Therefore, the RC allele could also 
be described as incompletely penetrant, able to induce severe ADPKD in combination with 
another pathogenic mutation. 
 
1.4.3 Gene dosage and networks 
As the dosage of PC1 has been found to be both increased and decreased in ADPKD tissue and 
animal models (Table 1.1), it has been questioned whether the dosage itself influences 
cystogenesis, or whether the dysregulation of this molecule has downstream consequences in 
gene networks. 
 
An early example of this is PAX2, which is known to play a role in kidney cell differentiation 
[78]. Transgenic ADPKD compound mutant mice carrying, in an addition to a homozygous 




inferring that perhaps reduction of Pax2 dosage may be equivalent to inhibition of factors 
involved in the signalling pathways (such as cMet, NF-𝜅B or Wnt) that form a regulatory 
cascade to activate Pax2 expression in kidney tubules. 
 
It is also been demonstrated that the protein kinase mTOR (mechanistic Target of Rapamycin) 
plays a role in ADPKD. mTOR plays a role in the coordination of cellular growth and 
metabolism, and is regulated by PC1 [80]. As a target of Rapamycin, this has been an 
investigated route for therapeutic treatment of ADPKD. While Rapamycin has lowered total 
kidney volume, this molecule, as a treatment for ADPKD, has been unsuccessful due to poor 
patient tolerance to side effects [16]. 
 
A recent study has demonstrated that the oncogene Myc is upregulated both in the absence and 
gain of polycystin-1 in transgenic mice [81]. Furthermore, the expression of PC1 was 
modulated by the overexpression of Myc, suggesting that there is a regulatory loop mechanism 
influencing pathogenesis. 
  
1.5 Polycystic Kidney Disease is a ciliopathy 
Cysts from ADPKD arise from the epithelial cells of the nephron. Renal epithelial cells have a 
primary (immotile) cilium protruding on the apical membrane, which can act as a 
mechanosensor to detect fluid flow within the lumen, in turn triggering an influx of intracellular 
Ca2+ (which has a role in cell signalling) [82]. 
 
ADPKD is considered a ciliopathy – a disorder of the cilia – due to evidence linking 
dysfunctional cilia with cystic kidney disease. In mice, inactivation of either the gene Kif3a or 




absence of cilia is not a feature in Pkd1 mutant mice nor ADPKD patients, so inactivation of 
Kif3a is not a requirement for the disease but it does infer that the impairment of cilia is crucial 
in ADPKD. 
 
PC1 and PC2 can both localise to the cilium [37, 84], where together they are thought to 
function as sensors of the extracellular environment (the renal tubular lumen) and initiate 
signalling cascades. Cultured renal epithelial cells from Pkd1– mutant embryonic mice do not 
respond to fluid flow sheer stress, while their wild-type counterparts do by increasing the 
intracellular Ca2+ concentration [85]. It is postulated that the large extracellular portion of PC1 
acts as a sensor, which results in a conformational change to activate PC2. 
 
Additionally, when wild-type renal epithelial cells were treated with an inhibitory antibody 
designed to target the intracellular portion of PC2, the cells continue to respond to fluid flow 
by increasing the concentration of intracellular Ca2+. However, when the same cells are treated 
with an antibody targeting the extracellular portion of PC2, the cells no longer respond to fluid 
flow [37]. 
 
In addition to ADPKD, there are various forms of renal ciliopathies, including Autosomal 
Recessive Polycystic Kidney Disease (ARPKD). This disease includes subtypes such as 
Nephronophthisis (NPHP) and Medullary Cystic Kidney Disease (MCKD) (Table 1.2). 
ARPKD is an inherited, recessive disease caused by the gene PKHD1. Recessive PKD is much 
less common than the dominant form, and often results in fetal or neonatal death [86]. It is 
generally accepted that ARPKD cysts arise from the collecting duct of the nephron, which 
expand but stay attached to their respective tubule [5]. In ADPKD it is believed the cysts bud 




proportion of ADPKD cysts contain collecting duct markers, ADPKD cysts are believed to 
arise from all segments of the nephron as well as the collecting ducts [87]. 
 
Table 1.2: A summary of the major renal ciliopathies 
Disease Genetic cause 
Age when 




Arise from all segments of the 






PKHD1 Neonates Derived from and remain 
connected to the collecting duct 
NPHP genes Infants - Adolescents Corticomedullary border 
MCKD1 
Primarily adults Within the medulla 
MCKD2 
 
NPHP, which is the primary cause of renal failure in children, is the result of recessive 
inheritance of one of a large number of identified NPHP genes, which affect adolescents, 
juveniles and infants. In this disease, cysts develop at the corticomedullary border of the kidney 
[88]. There are also multiple forms of MCKD, consequential of the dominant inheritance of 
MCKD1 or MCKD2 [89, 90]. In MCKD, cysts form exclusively within the medulla and result 
in the bilateral shrinkage of the kidneys. MCKD is typically milder than NPHP, and primarily 
affects adults.  
 
The development of hepatic cysts can occur in ADPKD patients, which is usually indicative of 
co-morbid Polycystic Liver Disease (PLD). PLD can occur as an independent disease or 
alongside ADPKD or ARPKD, however hepatic cysts typically do not affect liver function. 





1.6 Similarities between ADPKD and neoplasia 
ADPKD demonstrates similarities to a number of features associated with cancer, which is why 
it has been described as “neoplasia in disguise” [93]. Features of ADPKD align with eight of 
the ten hallmarks of cancer (Table 1.3) [94]. 
Table 1.3: Comparison of ADPKD and the hallmarks of cancer 
Adapted from Seegar-Nukpezah et al. (2015) [95]. 
Hallmarks of cancer ADPKD 
Genomic instability and mutation 
LOH has been proposed to initiate cystogenesis [68, 
74, 75]; emerging data that epigenetic changes 
contribute to cystogenesis [96]. 
ADPKD lymphocytes demonstrate high levels of 
DNA damage [97]. 
Sustaining proliferative signalling 
Elevation of epithelial proliferation in ADPKD cysts 
due to growth factors/cytokines/cAMP in cystic 
fluid. 
Evading growth suppressors Tumour suppressor signalling (such as p53) is dysregulated [98, 99]. 
Resisting cell death Low levels of apoptosis in cysts (elevated in 
parenchyma) [100]. 
Tumour-promoting inflammation 
Interstitial inflammation is observed in ADPKD 
[101]. This is thought to contribute to disease 
progression. 
Inducing angiogenesis Abnormal capillaries around renal cysts [102, 103]. 
Deregulating cellular energetics High rate of aerobic glycolysis in ADPKD [104]. 
Avoiding immune destruction Macrophages are thought to promote cyst growth 
through C3 induction [105]. 
Enabling replicative immortality 
Replicative immortality does not occur in ADPKD – 
replicative crisis is delayed in Pkd1-/- mouse embryo 
fibroblasts [98]. 
Activating invasion and metastasis Metastasis does not occur in ADKD. 
 
Most notably, both diseases can be characterised by genomic instability and mutation. In cancer, 
this is either due to heritable phenotypes or the “chance acquisition” of a mutant genotype 
causing the subclonal population of cells to proliferate over neighbouring cells [94]. Emerging 
data now recognises that epigenetic modification regulating gene expression is also an aspect 




PKD-causing gene (such as PKD1). The chance acquisition of mutant genotypes is the LOH 
proposed to occur in more than 10% of clonal cyst populations. 
 
Defects in the DNA-maintenance mechanisms within the genome have been documented in 
neoplasia [106], limiting the cell’s ability to repair or destroy misfolded proteins and to prevent 
further genomic damage. Interestingly, one of the genes recently attributed to PKD 
pathogenesis, GANAB, is involved in the quality control complex of the endoplasmic reticulum.  
 
Another similarity between neoplasia and ADPKD is that epithelial cells originating from renal 
cysts have sustained proliferative signalling, wherein molecules such as EGF, cAMP and 
cytokines contribute to cyst growth and are speculated to drive cystogenesis in an oncogenic 
fashion. The deregulation of apoptosis is also observed in both diseases, although in cancer this 
process is limited; in ADPKD apoptosis is increased in the parenchyma and marginally reduced 
in tubule epithelia. 
 
One key hallmark of cancer that ADPKD does not possess is the invasion and metastasis of 
malignant cells throughout other organs of the body. While cysts are observed in other organs 
(such as within the liver and intestines), these do not proliferate and cause organ failure in the 
same manner that the primary cysts within the kidney do, and there is no evidence to suggest 
they originate from migration of renal cysts. 
 
There are two fundamental characteristics of cystic cells in ADPKD which are not considered 
to be in the hallmarks of cancer: altered ciliary signalling, and the dysregulation of intracellular 





Available treatments for ADPKD are limited due to both the incomplete knowledge of the 
disease, and little financial incentive for pharmaceutical companies to develop 
ADPKD-specific products [95]. Additionally, a number of therapies have failed due to 
insufficient patient responses during clinical trials or poor patient tolerance to side effects. The 
similarities between ADPKD and cancer means that there is the possibility of therapeutics 
currently developed for use in cancers to be repurposed for use in ADPKD, some of which have 
already been the subject of clinical trials in ADPKD [16]. 
 
1.7 Epigenetic and post-translational influences in ADPKD 
In addition to germline or somatic mutations, gene and protein expression can be easily altered 
by epigenetic mechanisms. These are molecular changes that occur to the DNA molecule 
without changing the genetic sequence and are easily altered to change gene expression. 
Epigenetic factors are important for many reasons. During development, epigenetic 
mechanisms play a role in cellular growth and differentiation, and as cells mature, these 
epigenetic factors change to suit the role of a cell. Once the cell differentiates, epigenetic 
modifications are specific for every cell type. 
 
Two key forms of epigenetic regulation involve histone modification (such as acetylation and 
methylation) and DNA methylation. These mechanisms act to modify the chromatin state and 
accessibility of DNA to transcription factors. A similar biological mechanism is the 
post-translational regulation of genes by microRNA. The most significant mechanisms of 






microRNA are a class of non-coding RNAs, approximately 20 nucleotides long. These 
sequences function as post-translational regulators to alter protein expression by cleaving 
mRNA (as part of a silencing complex containing Dicer). It has been estimated that one third 
of protein coding genes may be regulated by miRNA [107]; in cancer it has been documented 
that a large number of genes are modified by specific miRNA. Some notable pathways 
regulated by miRNA include the anti-apoptosis gene BCL2 and the oncogene MYC [108]. 
 
miRNAs are transcribed from the genome as primary miRNA, which are then spliced with 
Drosha and Dicer enzymes to become mature miRNAs (Fig. 1.4). Mature miRNAs contain a 
“seed site”, which is a sequence estimated to be from six to ten nucleotides long that has the 
ability to target complementary sequences in the genome. Due to the frequency of the 
complementary sequence in the genome, each miRNA has the ability to transcriptionally 





Figure 1.4: Maturation and mechanism of miRNA 
miRNAs are transcribed from the genome with RNA Pol II. The primary miRNA is then modified by 
Drosha enzymes to become pre-miRNA. Pre-miRNA are further modified by Dicer. The mature miRNA 
can then form a complex with a RISC (RNA-induced silencing complex) to bind to a complementary 





1.7.2 miRNA in ADPKD 
Previous research in renal development has confirmed that miRNAs are required for embryonic 
development of the kidney, and several miRNAs have been implicated in glomerular and 
tubular diseases [111]. Screening of miRNA in tissue and plasma samples has identified a wide 
range of miRNA as being dysregulated in ADPKD. Current findings of miRNA dysregulation 
in ADPKD include the upregulation of miR-182-5p [112] and 199a-5p [113], as well as the 
downregulation of miR-192 and miR-194 due to hypermethylation [114]. It has also been 
demonstrated that miR-501-5p is upregulated in ADPKD, causing activation of the mTOR 
pathway through p53-mediated mechanisms [115]. 
 
Most recently, inhibition of the miR-17~92 cluster has been demonstrated to reduce cyst 
proliferation in ADPKD mice [116]. Further analysis of the six miRNAs within this cluster 
(miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, miR-92a-1) provides evidence that 
modulation of miR-17 alone is sufficient to attenuate the growth of cysts [117]. Additionally, 
the anti-miR-17 treatment in this study inhibited mTOR signalling. As mTOR has previously 
been assessed as a target for therapies in ADPKD (see Section 1.4.3), inhibition of miRNA 
suggests an additional target for treatment of the disease. 
 
1.7.3 Histone Modification 
DNA is wound around histone octamers, which allow for the tight packaging and organisation 
of the DNA molecule in the nucleus. The histone proteins contain many tails, to which a large 
range of chemical modifications can occur. These modifications determine how closely the 
histones are packaged together, in turn facilitating how freely DNA can be transcribed. There 





Acetylated histones result in relaxed chromatin (euchromatin) which is associated with greater 
levels of gene transcription, while deacetylation results in heterochromatin, which is tightly 
packed and has reduced levels of gene transcription (Fig. 1.5).  
 
 
Figure 1.5: Histone acetylation regulates gene transcription 
The modification of lysine residues attached to the histone octamers that DNA is wound around 
determines how tightly packaged the chromatin is. Euchromatin (upper) is associated with greater levels 
of gene transcription than heterochromatin (lower) which prevents transcriptional mechanisms from 
accessing the DNA. Chromatin packaging is modified by the attachment of acetyl group (Ac) to the 
lysine residues with histone acetyltransferases (HATs), or dissociation of acetyl group from the lysine 
residue with histone deacetylases (HDACs). 
 
Histone acetylation is catalysed with histone acetyltransferases (HATs), while deacetylation 
requires histone deacetylases (HDACs). There are several classes of HATs and HDACs, based 





1.7.4 Histone deacetylases in ADPKD 
While multiple mechanisms of histone modification are able to occur, there is little evidence of 
histone phosphorylation and methylation in the context of ADPKD. The regulation of histones 
with HDACs, however, has been well documented [96]. Some of the studies implicating HDAC 
activity in ADKD include p53-induced repression of the PKD1 promoter which has been shown 
to be attenuated with HDAC treatment [120], targeting of HDAC5 expression through 
polycystin-dependent fluid stress signalling [121], and HDAC6 inhibition preventing the 
release of Ca2+ from the endoplasmic reticulum, consequentially attenuating cyst growth 
through cAMP signalling [122]. 
 
Numerous studies have identified the activity of HDACs as a driver of neoplasia, due to the 
aberrant expression of HDACs in tumours [123], and the ability to use post-translational 
modification of histones with HDACs and HATs as biomarkers in human tumours [124]. As 
such, there are now several HDAC inhibitors that have been approved by the Food and Drug 
Administration (FDA) for the use in human cancer [125]. The class I HDAC inhibitor VPA, 
and class I and II HDAC inhibitor TSA have both been shown to reduced cyst formation and 
slow cyst growth in animal models [99, 120, 121, 126], yet these drugs are yet to show sufficient 
beneficial effects in human clinical trials and be approved by the FDA. 
 
1.7.5 DNA methylation 
DNA has the potential for nucleotides to be modified by the addition of a methyl group via 
DNA methyltransferase (DNMT) proteins. This typically occurs on cytosine residues which are 
immediately followed by guanine (CpGs), although DNA methylation can also occur at other 




in the genome [128], as DNA methylation is required for the controlled suppression and 
expression of genes (Fig. 1.6). 
 
 
Figure 1.6: DNA methylation as an epigenetic mechanism 
The addition of a methyl group to a CpG dinucleotide is created by DNMTs (or methylating agents). 
Unmethylated DNA can be facilitated by the inhibition of DNMTs, or demethylating agents. 
Hypomethylation of promoters and other enhancer elements allow the transcription of genes, while 
hypermethylation of promoters prevents the DNA machinery from accessing these regions to enable 
transcription. The inverse is seen in gene bodies, as hypermethylation at the 3’ end of a gene is often 
correlated with increased gene expression, although an explanatory mechanism for this is not clear. 
 
Clusters of CpGs are known as CpG islands, and these are often found in areas of high 
importance for gene expression, such as the promoter or enhancer regions of the genome [129]. 
Methylation at the promoter regions of the genome have historically been associated with the 
repression of a gene, by reducing the ability of transcription factors to bind [130]. One 
mechanism of transcription factor inhibition includes chromatin remodeling, suggesting that 
there is epigenetic cross-talk between DNA methylation and histone modification in the 





Methylation of CpGs within the gene body is not as well understood as that of the promoter, 
but typically results in sustained or increased expression of a gene [132, 133]. A variety of 
mechanisms have been proposed to explain this phenomenon. These all postulate that the 
methylated regions contain genomic elements, either responsible for alternative splicing, 
containing transcription factors which when hypomethylated interfere with the host gene 
expression, or as residual epigenetic marks from embryonic stages of development [132]. 
 
DNA methylation is required at all stages of life, from differentiation of embryonic stem cells 
during development [134], to the maintenance of X inactivation [135] and specialization of 
cells [136]. The pathology of several diseases, most notably cancers, has been linked to 
dysregulation of DNA methylation both globally and locally [137]. As such, DNMT inhibitors 
have been developed as a therapeutic drug for certain cancers [138]. 
 
1.7.6 DNA methylation in ADPKD 
A 2014 paper by Woo et al. [139] was the first to report global DNA methylation in ADPKD 
patients. This was conducted with pyrosequencing on the kidney tissue from three patients with 
ADPKD (and three from non-ADPKD tissue). The results from this analysis identified over 
13,000 unique fragments in the genome which were differentially methylated; 91% of these 
were found to be hypermethylated. The exonic region of the genome was found to be the major 
target of DNA methylation changes in ADPKD, with 5.93-fold higher hypermethylation 
occurring at these regions. 
 
This group also analysed DNA methylation in the PKD1 gene body (exon 43), and 
demonstrated hypermethylation in ADPKD samples, negatively correlating with the expression 




mRNA, and treatment of the cyst-forming cell line MDCK with a DNMT inhibitor repressed 
the growth of cysts. 
 
Inhibition of DNMTs has been developed as a therapeutic for various neoplasia [137]. It is 
theorized that if the hypermethylation of ADPKD was resulting in cystogenesis, the same 
pharmaceuticals could be used for the treatment and management of ADPKD patients. 
 
1.8 Rationale for study 
Preliminary data from a previous student [140] showed global hypomethylation in an analysis 
of ADPKD tissue from two patients. This was in contrast to the previously reported study which 
identified hypermethylation as a contributing factor to ADPKD [139]. As there are so few data 
currently available on DNA methylation in ADPKD, my first aim in this study was to analyse 
further ADPKD tissues, to add to the previous research performed in our laboratory on the 
methylation of tissue from ADPKD kidneys. 
 
All previous work on the ADPKD methylome has been performed using whole tissue samples, 
which contain multiple ADPKD cysts. As cysts are thought to arise independently, one of my 
specific aims in this study was to identify whether changes seen in ADPKD whole tissue are 
representative of the ADPKD methylome, or whether cysts each contain their own unique 
methylation pattern.  
 
1.9 Hypothesis 
I hypothesise that there will be significant differences in the methylome of ADPKD tissue and 
non-ADPKD kidney. I further hypothesise that there will be multiple differentially methylated 






• To use reduced representation bisulfite sequencing (RRBS) to identify key regions of 
differential methylation in a larger panel of ADPKD kidney tissue. 
• To use RRBS to show the (representative) methylome of ADPKD cysts and determine 
whether the changes seen in whole tissue are seen consistently in individual cysts. 
• To investigate the three miRNAs associated with CpG islands in the PKD1 gene and 








2.1 Sources of nucleic acids for genetic analysis 
DNA and RNA isolated for this research came from kidney tissue from ADPKD patients and 
healthy individuals, as well as ADPKD-derived cell lines. One patient has a confirmed germline 
PKD1 mutation. The remining four patients are assumed to have PKD1 mutations, based upon 
the age of patients at time of nephrectomy, however these patients have not been genotyped. 
Data about each sample such as age and sex can be found in Appendix A. The use of human 
tissue samples was approved by the Otago Human Ethics Committee H15/H110. 
 
2.1.1 Kidney tissue dissection 
Tissue segments were dissected from the kidneys of ADPKD patients immediately following 
renal transplantation at Dunedin Hospital. Multiple segments were cut from the cortex of the 
kidney (although this region is not clearly defined in ADPKD due to the extent of cyst growth, 
thus the location was approximated), in which each tissue section contained tissue from 
multiple cysts as well as blood cells, connective tissue, fibrous tissue and any remaining 
parenchyma. Tissue samples were cut from multiple regions in the kidney by grasping a 
segment of tissue with forceps and cutting it out with surgical scissors. Samples were 
immediately frozen in liquid nitrogen for storage at -80 ºC. 
 
An additional kidney in this analysis was treated with neutral buffered formalin (NBF) for seven 
days prior to dissection. The selection of tissue segments was carried out in the same manner 
as above but were stored in 70% EtOH for 24 hours before embedding in a paraffin block (rather 
than freezing at -80 ºC). 





Segments of non-ADPKD tissue were provided by the Christchurch Tissue Bank. These 
samples were collected from the cortex of the kidney during renal tumour surgery – dissected 
as far from the tumour as possible, and with histological testing to confirm the absence of 
malignant tissue – which were collected fresh and frozen at -80 ºC when delivered to our 
laboratory. The non-ADPKD tissue was used as the control group in this study, as by the time 
ADPKD patients undergo nephrectomy, the disease has developed to an extent where the 
kidneys contain no unaffected tissue that could be used as a direct comparison against cystic 
tissue. 
 
2.1.2 Isolation of cyst wall tissue from an ADPKD kidney 
In addition to segments of tissue, sections of cyst wall were also dissected from an ADPKD 
kidney. These samples were intended to only contain tissue from a single cyst wall, thereby 
providing a more precise picture of the methylation landscape in cystic tissue. These samples 
were excised from an ADPKD kidney that had been treated in NBF for 24 hours and rinsed 
with 70% EtOH to wash off any sources of contaminating DNA (such as blood cells) from the 
cyst wall. These samples were submerged in EtOH and stored at 4 ºC. 
 
2.1.3 Immortalised cell line growth 
The two cell lines used in this analysis were renal epithelial cells WT 9-7 (ATCC® CRL-2830™) 
and WT 9-12 (ATCC® CRL-2833™), each derived from an independent cyst of a female 
ADPKD patient. The cell lines have been characterised as having originated from a proximal 
tubule based upon CD13 antibody staining and LTA lectin binding (although the WT 9-12 cell 




cells both carry the truncating PKD1 mutation Q2556X – WT 9-7 is heterozygous for this 
mutation while WT 9-12 is homozygous [141]. 
 
Cells were grown on flasks coated with type I collagen (0.05 mg/mL) in DMEM media (Table 
2.1). The cells were grown at 37 ºC with 5% CO2 for ten days, during which time they went 
through one passage. Cells were lifted with Trypsin-EDTA (0.25%) and spun down at 300 g 
for five minutes. The supernatant was aspirated, and the pellets were stored at -20 ºC until 
required for DNA and RNA extraction.  
Table 2.1: DMEM media for cell culture 
Dulbecco's Modified Eagle Medium (DMEM) 89%  
Penicillin-Streptomycin (10,000 U/mL) 1%  
Fetal Calf Serum 10%  
 
2.1.4 DNA isolation from cells and tissue 
DNA was extracted from the cell line pellets using a QIAmp DNA Mini kit (Qiagen, cat. no. 
51304). All elutions followed the manufacturer’s instruction. 
 
Approximately 25 mg of tissue was cut from the frozen kidney segments over dry ice with a 
clean razor blade. The ADPKD samples required further maceration with the blade to assist 
with the homogenization steps, as they are fibrous and difficult to breakdown in the following 
steps. The samples were then transferred to a 2 mL microcentrifuge tube to grind with a clean 
pestle, then homogenized in a QIAShredder column (Qiagen, cat. no. 79656) before continuing 
with the QIAmp DNA Mini kit protocol. 
 
DNA was isolated from cyst wall samples, which had been treated with NBF, with the QIAmp 




was increased from one hour to overnight (approximately 16 hours) to ensure maximum lysing, 
and the ATE incubation was extended to five minutes to increase the final yield of DNA. 
 
2.1.5 RNA isolation from cells and kidney tissue 
RNA was extracted from the cell line pellets and fresh-frozen kidney tissue segments using a 
miRNeasy Mini kit (Qiagen, cat. no. 217004). As above, 25 mg of the tissue samples were cut 
over dry ice and macerated with a clean razor blade. The miRNeasy protocol was followed as 
per the manufacturer’s instruction to isolate total RNA. 
 
The segment of ADPKD kidney in paraffin was sliced into four sections 10 µm thick, and RNA 
was extracted using the miRNeasy FFPE kit (Qiagen, cat. no. 217504). Deparaffinisation was 
performed with xylene, and the manufacturer’s instructions were followed after this point. 
 
2.2 Creation of reduced representation bisulfite sequencing libraries 
The methylome of samples in this research was generated using a method known as reduced 
representation bisulfite sequencing (RRBS), wherein a fraction of the genome enriched with 
CpG sites is amplified and sequenced to provide an overall picture of the methylation across 
the whole genome.  
 
This protocol is comprised of six key steps (summarised in Fig. 2.1). It is based upon published 
protocols [142], although it has been modified to allow a lower quantity of input DNA. Key 
processes of the protocol are detailed in the following sections. Prior to the development of this 
protocol, five whole tissue samples were generated from 2.5 µg of DNA by a previous student 
[140], and the cell line libraries were generated from 2.5 µg of DNA with the assistance of 





Figure 2.1: Summary of the RRBS protocol 
RRBS libraries are generated from DNA isolated from kidney tissue. (i) The DNA is fragmented at CpG 
sites using an MspI digest. (ii) Fragments are then modified to repair sticky ends (grey), (iii) an A-tail 
(green) is added to the 3’ end of each fragment, (iv) and a sequencing adaptor (purple) ligated to the A-
tail. (v) The library is then bisulfite converted, creating single stranded fragments with uracil (yellow) 




2.2.1 MspI digest 
An MspI restriction enzyme digest was set up for each sample (Table 2.2) and incubated at 
37 ºC overnight. Low-bind tubes were used for this and all subsequent steps performed in the 
thermal cycler to minimise the loss of DNA due to sample-tube binding.  
Table 2.2: MspI restriction enzyme digest 
DNA sample ~0.5 µg  
NEB MspI (20 U/µL) 8.0 µL  
10x NEB Buffer 4 3.0 µL  
MQ H2O To 30.0 µL  
Total 30.0 µL  
 
Once digested, libraries were purified with the QIAQuick PCR Purification kit (Qiagen, cat. no. 
28104) and eluted into 60.0 µL. 
 
2.2.2 Fragment repair 
Following the digest and purification, samples were incubated with End Repair Mix 2 according 
to Table 2.3 at 30 ºC for 30 minutes. 
Table 2.3: Fragment repair for one RRBS library 
MspI-digested DNA sample  60.0 µL   
End Repair Mix 2 40.0 µL   
Total 100.0 µL   
 
This sample was then purified with the MinElute PCR Purification kit (Qiagen, cat. no. 28006) 
and eluted into 17.5 µL. 
 
A 30A overhang was formed at the 3’ end of each fragment using A-Tailing Mix (Table 2.4). 






Table 2.4: A-Tailing 
DNA sample 17.5 µL  
A-Tailing Mix 12.5 µL  
Total 30.0 µL  
 
To the A-Tailed sample, adaptors with a 30T overhang were bound to the fragments in each 
library, set up as in Table 2.5 in a preheated thermal cycler at 30 ºC for ten minutes. Unique 
adaptor sequences were selected for each library, based on the published sequencing guidelines 
for multiplexing [143], which allows for multiple libraries to be pooled together and sequenced 
across the same lanes. 
Table 2.5: Adaptor ligation 
 
Immediately following ligation, 5 µL of Stop Ligase Mix was added to each sample, and a final 
MinElute PCR Purification was carried out. 
 
2.2.3 Bisulfite conversion 
To identify the methylation status of the DNA, samples underwent bisulfite conversion. 
Although two different kits were used (EZ DNA Methylation-Direct, Zymo, cat. no. D5020 and 
MethylCode Bisulfite Conversion, Invitrogen, cat. no. MECOV50), the reagents and protocols 
used are the same. 
 
The protocol for each kit was followed, each time using freshly prepared CT reagent, as this is 
only stable for a short period of time, and subject to degradation when exposed to UV light. 
Once converted, the remaining library preparation steps were carried out within 24 hours, as 
single-stranded bisulfite converted libraries are not as stable as double stranded genomic DNA. 
DNA sample 60.0 µL  
RSB Buffer 2.5 µL  
DNA Adaptor 2.5 µL  
Ligation Mix 2 2.5 µL  





2.2.4 Semi-quantitative PCR 
A PCR reaction was set up for each library (Table 2.6) and split in two tubes. Each sample 
underwent thermal cycling at 15 and 20 cycles (Table 2.7). 
 
Table 2.6: PCR master mix 
10x PfuTurbo Cx Reaction Buffer 2.5 µL  
2.5mM dNTP Stock (3.3 mM final) 3.0 µL  
TruSeq PCR Primer Cocktail 3.0 µL  
DNA Sample 3.0 µL  
PfuTurbo Cx HotStart DNA Polymerase 1.2 µL  
MQ H2O 12.3 µL  
Total 25.0µL  
 
Table 2.7: Thermal cycling conditions for library amplification 
With the semi-quantitative analysis, n = 15 or n = 20 cycles; in large scale amplification, n = the number 
determined by semi-quantitative PCR analysis. 
 95 ºC 2 minutes  
Denaturation 95 ºC 30 seconds 
x n cycles Annealing 65 ºC 30 seconds 
Extension 72 ºC 45 seconds 
 72 ºC 7 minutes  
 4 ºC hold  
 
A 3% (w/v) NuSieve gel was prepared by mixing NuSieve™ GTG™ agarose (Lonza, cat. no. 
50081) in a glass bottle with freshly prepared 0.5 X TAE buffer, heating in small increments in 
a microwave at 50% power until the powder is fully dissolved. The gel was then poured into a 
tray with a 12-toothed comb and left to set for an hour. Once set it was placed in the 
electrophoresis tank, submerged but not covered in freshly prepared 0.5 X TAE buffer. 7 µL of 
25 bp DNA ladder (Invitrogen, cat. no. 10597011) was loaded into the first well, and PCR 
products were loaded in pairs with 3 µL Xylene Cyanol (XC) loading dye. The gel was run at 
50 V for 5 minutes, then paused as additional 0.5 X TAE buffer was added to the tank to 




NuSieve™ gel prevents PCR products from rising out of the well (which can happen due to 
remaining EtOH in the sample). 
 
Once the gel was run for a total of 90 minutes, the gel was visualised under UV in the BioRad 
GelDoc. The resulting image (see Appendix B) was used to judge the number of cycles required 
to successfully amplify the remaining library, by comparing the brightness of bands between 
150 and 325 bp. These decisions were supported with advice from senior researchers in the 
laboratory who have experience with this protocol. 
 
2.2.5 Large scale amplification 
PCR master mix was prepared (Table 2.8) and amplified under cycling conditions determined 
by the semi-quantitative PCR. For each library, the DNA and master mix solution was pipetted 
across an 8-tube strip of 0.2 mL microcentrifuge tubes in volumes of 12 µL, replicating the 
surface area of the semi-quantitative PCR. Once amplified, the PCR products were pooled from 
the 8-tube strip into a 2 mL microcentrifuge tube and purified with a MinElute PCR Purification 
kit. 
Table 2.8: Large scale PCR master mix 
10x PfuTurbo Cx Reaction Buffer 10.0 µL  
2.5mM dNTP Stock (3.3 mM final) 12.0 µL  
TruSeq PCR Primer Cocktail 12.0 µL  
DNA Sample 12.0 µL  
PfuTurbo Cx HotStart DNA Polymerase 4.8 µL  
MQ H2O 49.2 µL  
Total 100.0 µL  
 
2.2.6 Size selection 
In order to isolate the RRBS library from the adaptors and any DNA fragments remaining in 
the sample, libraries were run through another 3% (w/v) NuSieve gel as prepared above. Fresh 




of 25 bp DNA ladder was loaded into the first well, and libraries (18 µL of DNA and 2  µL of 
XC loading dye) were loaded into every second well, with a maximum of four libraries on any 
gel. The gel was run at 50V for a few minutes, and once the samples were seen to move into 
the gel, and tank was paused and 0.5 X TAE buffer was added to fully cover the gel. The gel 
was then run at 50 V for a total of 90 minutes.  
 
Once this was completed, the gel was carefully removed from the tank and placed on a clean, 
sterile surface (a T75 cell culture flask was used). The first lane containing the ladder was cut 
from the gel with a clean razor blade and transferred to the GelDoc to visualise and measure 
the DNA ladder without exposing the RRBS libraries to the UV lamp. Using a ruler laid 
alongside the lane, the distance to the 150 and 325 bp bands was measured (Fig. 2.2). 
 
Lanes containing the library were cut from the gel with a clean razor blade. Perpendicular cuts 
were made at the 150 bp and 325 bp points, using the ruler laid alongside as a reference. Each 
cut was made with a new razor blade, to eliminate the likelihood of contamination from the 
larger DNA fragments and smaller adaptor dimers on the blade surface. 
 
The section of the gel containing the library was then placed into a 2 mL LoBind 
microcentrifuge tube (Eppendorf, cat. no. 022431048) to perform a MinElute Gel Extraction 
(Qiagen, cat. no. 28604); sections weighing over 400 mg were split into two tubes. The 
remaining agarose was pieced together and imaged under UV in the GelDoc to confirm the 







Figure 2.2: Illustration of size selection and gel extraction 
A) Expected RRBS library following large-scale library amplification. B) The lane containing a 1 kb 
ladder is cut from the gel and imaged under UV; distance to the 150 and 325bp bands is measured on a 
ruler. C) Lane containing RRBS library is cut from gel. The gel is cut at the distances measured from 
the ladder to excise solely the section of the gel containing RRBS library. 
 
2.2.7 Library preparation 
Isolated libraries were quantified with the Qubit 2.0 Fluorometer (Life Technologies) with the 
dsDNA HS Assay (Invitrogen, cat. no. Q32851), before being sent to Otago Genomics Facility 
(OGF) to be run through the 2100 Bioanalyzer. 
 
Several libraries required an additional round of size selection, when initial bioanalyzer traces 
indicated adaptor contamination. For this, AMPure XP Beads (New England BioLabs, cat. no. 




Bead size selection does not lose as much of the DNA library as an additional gel extraction. 
These samples were run through the bioanalyzer again before continuing with sequencing. 
 
Libraries were diluted in Qiagen elution buffer 10 nM in 10 µL solutions for high-throughput 
sequencing on the Illumina HiSeq 2500 with single-ended 100 bp reads. Some libraries had a 
yield too low to prepare a 10 nM solution from, and so smaller quantities of DNA were 
submitted (as listed in Appendix C). 
 
2.3 Analysis of sequencing data 
The libraries produced in Section 2.2 were mapped to the human genome. The resulting 
alignments were used alongside additional RRBS libraries from ADPKD and non-ADPKD 
tissue previously generated in our laboratory, to analyse the methylome of ADPKD. Analysis 
was performed with DMAP programs [144] in command line and with RStudio functions. An 
outline of the protocol is detailed below, step-by-step examples of the programs are in 
Appendix D. 
 
2.3.1 Preparation of sequencing alignments 
Each file was trimmed using the program cleanadaptors (v 1.35), which trimmed the 5’ and 3’ 
ends of each fragment to remove residual adaptor sequence from being included in the 
subsequent analyses. Sequence quality was checked with fastqc (v 0.11.5), and the resulting 
file was opened in a web browser to check for features such as overrepresented sequences. 
Overrepresented sequences indicate that adaptor sequences are still present in the library and 
the file should be further trimmed with more stringent criteria. The switches -t and -T instruct 
the program how far to cut off the 5’ and 3’ end of the fragment, respectively, and -x rejects 





As the samples had been sequenced across multiple lanes, each sample had multiple files (i.e. 
three for each individual ADPKD cyst) which were merged together to create a single file per 
library. 
 
The fastq files were mapped to the human genome (GRCh37/hg19 construct) using bismark 
(v 0.16.1), which generates a bam file. 
 
A non-ADPKD reference genome was created from all three non-ADPKD libraries using 
samtools (v 1.3), which could be used to compare against all ADPKD cyst libraries. 
 
 
2.3.2 Analysis of RRBS data 
Text files of the methylation data were generated using diffmeth (v 1.75). In all cases, the 
following switches were used: -F 2 (requires every fragment to contain two or more CpGs) and 
-t 10 (each fragment must contain ten or more reads). Additionally, all fragments used in 
analyses were to be between 40 and 220 bp in length. 
 
Lists of all RRBS fragments in a sample were generated with the switch -L. ANOVA analysis 
between two groups (-R and -S) were performed with the switch -B. 
 
The files generated from diffmeth analysis were annotated with identgeneloc (v 0.15), which 





2.3.3 Post-processing of RRBS data 
Once generated by DMAP programs, data was further analysed in RStudio. 
 
The lists of all RRBS fragments in each sample were compiled into one data frame, and the 
merge function was used to create a data frame of fragments common between all nineteen 
libraries. Pearson’s correlation coefficient (PCC) was calculated using this data frame to assess 
the similarities between samples. 
 
Global methylome analysis was performed with a Wilcoxon rank sum test for each library. 
Hyper- and hypomethylation trends were calculated between the median methylation values of 
the libraries. Violin plots were generated, which visually demonstrated trends across the whole 
genome. 
 
To identify the DMFs in ADPKD tissue, the p values calculated by ANOVA analysis in 
diffmeth were adjusted using False Discovery Rate (FDR) to account for multiple testing. The 
difference between non-ADPKD and ADPKD methylation was calculated and fragments with 
an absolute difference greater than 10% with an FDR-adjusted p value < 0.05 were identified 
as DMFs. 
 
Two methods of clustering were applied to the data sets. The first was unsupervised hierarchical 
clustering, which was performed on the common analysed fragments of all 19 RRBS libraries.  
 
The second clustering technical was  applied to only the common analysed fragments from the 
eight ADPKD cysts. This approach used the program ConsensusClusterPlus [145] to estimate 





2.4 Gene expression 
The expression of ADPKD-associated gene PKD1 was investigated in ADPKD and non-
ADPKD tissue sources through qPCR. Additional qPCR was performed on the same samples 
for several of the DMF-associated genes (cDNA and analysis performed by me, qPCR of DMF 
genes performed by Michael Bates). 
 
2.4.1 cDNA generation 
cDNA was generated from total RNA extractions using High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, cat. no. 4368814), following the protocol without 
RNase inhibitor. 10 µL of total RNA (10 ng) from each sample was added to 10 µL of master 
mix (set up as in Table 2.9). The samples were incubated at 25 ºC for ten minute, 37 ºC for two 
hours and 85ºC for five minutes. 
Table 2.9: cDNA Reverse Transcription master mix 
10X RT Buffer 2.0 µL  
25X dNTP Mix (100 mM) 0.8 µL  
10X RT Random Primers 2.0 µL  
MultiScribe™ Reverse Transcriptase 1.0 µL  
MQ H2O 4.2 µL  
Total 10.0 µL  
 
2.4.2 Reference gene selection 
Four genes – B2M, EEF1A1, RPL27 and SRP14 – were selected as potential reference genes, 
as these have been used in previous studies of gene expression in ADPKD. Primers were 
prepared to 10 ng/µL (sequences in Appendix E) for qPCR with SYBR® Premix Ex Taq™ (Tli 
RNase H Plus) (Takara Bio, cat. no. RR420A). Reactions were performed in triplicate on a 





Table 2.10: qPCR reaction set up 
SYBR® Premix Ex Taq™ 5.0 µL  
PCR Forward Primer (10 µM) 0.2 µL  
PCR Reverse Primer (10 µM) 0.2 µL  
cDNA sample 1.0 µL  
MQ H2O 2.6 µL  
Total 10.0 µL  
 
The most suitable genes were required to show consistent expression across all the tissue 
samples, which was measured with the algorithm geNorm and reported as “M” and “CV” values 
in qbase+ [146, 147]. 
 
2.4.3 Quantification of PKD1 expression 
To calculate the relative expression of PKD1 in the tissue samples, qPCR was carried out in a 
96-well plate. Each sample underwent qPCR for two reference gene primer pairs and a primer 
pair that targets PKD1 (sequences in Supplementary Table E.1), all in triplicate and set up as 
per Section 2.4.2 on the LightCycler480. The Cq values were imported into qbase+, where the 
expression of PKD1 in each sample was normalised to geometric mean of the relative quantities 
of the two reference genes [146, 147]. 
 
2.4.4 Statistical significance 
In order to determine the statistical significance in PKD1 expression between ADPKD and non-
ADPKD samples, the p value was calculated by way of a non-parametric t-test. The 
Mann-Whitney U-Test was used between the two groups in Prism. 
 
2.4.5 miRNA expression 
The expression of miRNA within the PKD1 sequence was carried out using the TaqMan® 




includes the TaqMan® Advanced miRNA cDNA Synthesis (Applied Biosystems, cat. no. 
A28007), followed by the Advanced miRNA Assay (Applied Biosystems, cat. no. A25576). 
 
In this protocol, cDNA is produced from four consecutive reactions as outlined in the Advanced 
miRNA Assays User Guide. 10 ng of total RNA was used for cDNA synthesis.  The 
amplification of miRNA for qPCR analysis was performed on three target miRNA (Assay ID 
478639_mir, 479661_mir, 478303_mir) and the reference gene miR-191-5p (Assay ID 
477952_mir) with the TaqMan® Fast Advanced Master Mix as recommended by the 
manufacturer. 
 
miRNA data was analysed on qbase+ by normalising the Cq expression of the genes to the 








Reduced representation bisulfite sequencing (RRBS) libraries were created from two ADPKD 
samples as per the methodology in Section 2.2. These sequencing data were analysed with 
RRBS data from an additional two ADPKD and three non-ADPKD tissue samples (prepared 
by a previous Master’s student in our laboratory [140]). 
 
The purpose of this was to create data representative of the methylome of ADPKD and non-
ADPKD kidneys to elucidate the differences between the two groups and demonstrate key 
differences that occur in ADPKD. The methylome analyses presented in this chapter have since 
been published [148] and can be read in Appendix F. 
 
3.1 Source material 
3.1.1 Kidney tissue 
Samples from one of the ADPKD kidneys used in this analysis (ADPKD D) were collected 
immediately following nephrectomy. This kidney weighed 1,164 g, and morphology was 
difficult to distinguish due to the presence of numerous cysts throughout the kidney (Fig. 3.1). 
It was noted that the centre of the kidney appeared to contain a large volume of adipose tissue, 
approximately where the medulla may be located. 
  





Multiple sections of tissue were collected from this kidney, and two sections were used in this 
analysis to provide biological and technical replicates (eventually to be called samples ADPKD 
D I, II and III). The second sample of ADPKD tissue prepared in this study (ADPKD 05) was 
donated in 2005 and had been stored at -80 ºC. All samples used in this analysis are summarised 
in Table 3.1. 
 
 
Figure 3.1: ADPKD kidney following nephrectomy 
The left kidney from patient ADPKD D (1,164 g) was dissected for collection of whole tissue ADPKD 
samples. A) Large fluid-filled cysts characteristic of ADPKD are throughout the entire kidney. B) The 
kidney, opened along the coronal plane, is filled with cysts. A large deposit of what appears to be adipose 






Table 3.1: Sample summary 
Tissue was sourced from three non-ADPKD patients (blue) and six ADPKD patients (red). Of the 
ADPKD samples, biological replicates were generated from repeat analyses of patient ADPKD D, and 
one pair of technical replicates was prepared from this same patient. Cell lines originally isolated from 
the same patient were also biological replicates. qPCR analyses were performed with tissue samples 
from three non-ADPKD patients and five ADPKD patients (whole tissue only). Patient ADPKD W 
tissue was only used for qPCR (not RRBS). 
Patient Tissue type Biological and technical 
replicate origin 




Non-ADPKD E Fresh-frozen   Non-ADPKD E 2.5 µg 10 ng 
Non-ADPKD G Fresh-frozen   Non-ADPKD G 2.5 µg 10 ng 
Non-ADPKD H Fresh-frozen   Non-ADPKD H 2.5 µg 10 ng 
ADPKD 05 Fresh-frozen   ADPKD 05 0.5 µg 10 ng 
ADPKD 07 Fresh-frozen   ADPKD 07 2.5 µg 10 ng 




Tissue Sample 1 ADPKD D I 0.5 µg 
10 ng 
Tissue Sample 2 
ADPKD D II 0.5 µg 




 Cyst 1 0.5 µg - 
 Cyst 2 0.5 µg - 
 Cyst 3 0.5 µg - 
 Cyst 4 0.5 µg - 
 Cyst 5 0.5 µg - 
 Cyst 6 0.5 µg - 
 Cyst 7 0.5 µg - 
 Cyst 8 0.5 µg - 
ADPKD W Formalin   ADPKD W - 10 ng 
WT 9 Cell line 
Proximal tubule WT 9-7 2.5 µg - 












3.1.2 Generation of RRBS libraries 
RRBS libraries were generated from small sections of kidney tissue (approximately 25 mg). It 
was noted that one section of ADPKD D tissue (which would generate sample ADPKD D I) 
was distinctly redder than the second ADPKD D sample, which appeared to be more fibrotic 
(and generated samples ADPKD D II and III, which were technical replicates of each other). 
Libraries were generated from 0.5 µg of DNA using the modified RRBS methodology in 
Section 2.2. 
 
3.1.3 Assessing the quality of data procured for this analysis 
Mapping and bisulfite conversion rates were calculated for the processed RRBS files to ensure 
they were of sufficient quality (Table 3.2). While all libraries had bisulfite conversion > 98%, 
only the ADPKD D sample with the highest coverage and mapping efficiency (ADPKD D III) 
was selected for further analysis in this section of the research project and will be referred to as 
‘ADPKD D’ in the remainder of this chapter. 
 
Table 3.2: Coverage and mapping efficiency of generated RRBS libraries 












ADPKD D I 9.95E+06 4.75E+06 47.70% > 98% 
ADPKD D II 1.43E+07 7.26E+06 50.80% > 98% 
ADPKD D III 1.42E+07 7.70E+06 54.20% > 98% 
ADPKD 05 1.86E+07 1.01E+07 54.20% > 98% 
 
The sequences underwent quality control by FastQC analysis, which analyses each sequenced 
fragment and assigns a quality score based upon the ability to identify nucleobases at each 
position in a sequence. This is represented by a box and whisker plot (Fig. 3.2) which plots the 




is expected that good quality sequences should have an IQR scoring above 28, which estimates 
accuracy of base-calling at 99.9%. Additionally, sequenced libraries with IQR scores falling 
below 20 (accuracy of base-calling ≤ 90%) should be trimmed to eliminate poor quality reads. 
 
The quality analysis of the RRBS libraries for ADPKD 05 and ADPKD D had sufficient quality 




Figure 3.2: Quality score of RRBS library ADPKD 05 
The quality of RRBS fragments across the sequenced lengths is represented by a box and whisker plot. 
The above sample, ADPKD 05, is representative of the sequence quality observed in all of the RRBS 
libraries generated in this project. It is typically recommended that when the interquartile range is above 
28 (green), the sequencing data is of good quality, and then it drops below 20 (red) the sequences should 





3.1.4 Validation of the RRBS protocol for assessing the methylome of kidney tissue 
Pearson’s correlation coefficient (PCC) values were calculated between each pair in the RRBS 
analysis (Table 3.3). These measure how far the observed data lie from the line of perfect 
concordance. Therefore, the variation between libraries can be measured as 1 PCC. These data 
validate the accuracy of the RRBS protocol, and also provide insight into the relationship 
between methylomes of kidney tissue in different groups (Table 3.4). A definition of correlation 
for highly similar objects has been described as: < 0.90 as poor, 0.90-0.95 as moderate, 
0.95-0.99 as substantial and > 0.99 as almost perfect concordance [149]. 
 
Table 3.3: Pearson’s correlation coefficients between pairs of RRBS libraries 
Libraries 05, 07, 08, D I, D II and D III are ADPKD samples, while E, G and H are non-ADPKD tissue. 
All pairs p < 2.2E-16. 
 
Technical replicates (ADPKD D II and III) were the most closely related (PCC = 0.993) in this 
group, which supports the validity of the RRBS methodology to accurately replicate the 




 05 07 08 D I D II D III E G 
07 0.989        
08 0.990 0.990       
D I 0.969 0.976 0.965      
D II 0.982 0.982 0.981 0.973     
D III 0.982 0.982 0.981 0.972 0.993    
E 0.972 0.976 0.977 0.953 0.982 0.982   
G 0.967 0.971 0.972 0.945 0.976 0.977 0.989  




Table 3.4: Mean PCC between experimental variables 
Mean PCC values calculated from data available in Table 3.3. 
 Mean PCC 
Technical Replicates 
Samples prepared from the same DNA extraction 0.993 
Biological Replicates 
Samples from the same patient; different DNA extractions 0.972 
Unrelated ADPKD 
Samples from unrelated ADPKD patient libraries 
0.982 
ADPKD v Non-ADPKD 
Comparisons between ADPKD and non-ADPKD libraries 0.973 
Unrelated Non-ADPKD 
Samples from unrelated non-ADPKD libraries 0.987 
 
3.2 Methylation in kidney tissue 
3.2.1 The global methylome in kidney tissue 
There were 345,711 fragments shared between ADPKD (n = 4) and non-ADPKD (n = 3) groups 
which satisfied the criteria of containing at least two CpGs and a read depth of at least ten at 
each fragment site. The coverage from each individual RRBS library is in Table 3.5. These 
fragments also had to be present in at least two of the ADPKD and two of the non-ADPKD 
libraries. This group of fragments was termed the analysed fragments, which covered 1,791,585 
CpG sites.  
Table 3.5: Coverage of RRBS libraries 
Fragments were required contain two or more CpGs with a read depth of 10 or higher, and to be in at 
least two non-ADPKD and two ADPKD samples in order to be included in analysed fragments pool. 
 Fragments analysed CpGs covered 
Non-ADPKD E 342,174 1,772,557 
Non-ADPKD G 313,924 1,619,926 
Non-ADPKD H 342,028 1,768,358 
ADPKD 05 250,407 1,353,018 
ADPKD 07 341,981 1,757,350 
ADPKD 08 340,723 1,762,144 
ADPKD D 170,346 957,481 






Total methylation within each of the whole tissue libraries is illustrated in Fig. 3.3. It is noted 
that the ADPKD D library has a significantly lower coverage and median methylation. The 






Figure 3.3: Global methylome of RRBS libraries 
The total sequenced methylome of each whole tissue RRBS library (n listed in Table 3.5). Median values 
(represented by the black bar on each violin plot) are on average lower in the ADPKD (red) samples 
compared to non-ADPKD (blue). The methylation values from the non-ADPKD (blue) and ADPKD 
(red) libraries are plotted where the median value is represented by the white dot. The distribution of 
methylation values are represented by the shape and area of the violin plot. Sample ADPKD D has less 
coverage of highly methylated fragments, as the kernel density in the area between 0.8 and 1.0 
methylation is not as wide as the other samples. 
 
 
Figure 3.4: Total methylation within genomic elements of ADPKD and non-ADPKD tissue  
The methylation beta values extend from 0 (no methylation in a fragment) to 1 (all CpGs are methylated 
in a fragment). The methylation values from the non-ADPKD (blue) and ADPKD (red) libraries are 
plotted where the median value is represented by the white dot. The distribution of methylation values 






























The median methylation value of the ADPKD tissue group was 0.56, whilst the non-ADPKD 
tissue group had a median methylation score of 0.58. This demonstrates a small but statistically 
significant trend of hypomethylation in ADPKD tissue (p < 2.2E-06, Wilcoxon rank sum test). 
Because sample ADPKD D had a significantly lower median, the global median of the other 
three ADPKD libraries was plotted to check that this library had not created a bias in the 
analysis. The global median value of methylation of libraries ADPKD 05, 07 and 08 was also 
0.56 (Supplementary Fig. G.1).  
 
The violin plot of genomic elements (Fig. 3.4) indicates a small amount of global 
hypomethylation in the intron, exon and intergenic fragments, as well as the same trend of 
global hypomethylation seen in Fig. 3.3 (Wilcoxon rank sum test p < 2.2E-16, Table 3.6). 
 
Table 3.6: Significance of differences in methylation seen in ADPKD tissue 
Median difference is calculated as methylation of non-ADPKD tissue subtracted from ADPKD tissue; 
negative values indicate hypomethylation of ADPKD. The significance was assessed with a Wilcoxon 
rank sum test (W). 
 Median difference W p 
Genome-wide -0.0214 6.3755E+10 < 2.2E-16 
Promoter -0.0102 2.9147E+9 < 2.2E-16 
Intron -0.0217 9.0363E+9 < 2.2E-16 
Exon -0.0317 5.9062E+8 < 2.2E-16 
Intron/Exon -0.0029 1.3295E+8 < 2.2E-16 







3.2.2 Differentially methylated fragments in ADPKD tissue 
Of the 345,711 analysed fragments in the whole tissue analysis, a total of 13 differentially 
methylated fragments (DMFs) were identified (Fig. 3.5). These were distinguished using the 
criteria set out in Chapter 2 (difference in methylation between ADPKD and non-ADPKD ≥ 10% 






























Figure 3.5: Methylation of non-ADKPD and ADPKD tissue at DMFs 
DMFs (pages 58, 59) were calculated from ANOVA analysis and have a difference in methylation > 10% 
and FDR-adjusted p value < 0.05. Bars show mean value ± SD, FDR-adjusted p values: * = p < 0.05, 





There was an enrichment of DMFs within intergenic regions and intron regions (Fig. 3.6), 




Figure 3.6: Distribution of genomic elements in DMFs 
A) Distribution of elements in analysed fragments (n = 345,711). B) Distribution of elements in 
identified DMFs (n = 13).   
 
Eight of these DMFs demonstrated hypomethylation in ADPKD, with a difference in 
methylation ranging from 0.10-0.43 between the two groups (Table 3.7). Two of these 
hypermethylated fragments were located within the gene body of protein coding genes. Two 
fragments were located between 5 kb upstream and1 kb downstream from the transcription start 
site (TSS) of a protein coding gene, and therefore are classed as being located within the 
promoter regions. The remaining four fragments were further than 5 kb from a protein coding 






Table 3.7: Differentially methylated fragments which show hypomethylation in ADPKD 
Fragments are identified by their location within the chromosome and the nearest protein-coding gene. 
The difference in methylation is calculated by subtracting the methylation score of non-ADPKD from 
that of ADPKD. The relationship to TSS refers to the distance between the fragment location and the 
transcription start site of the nearest protein-coding gene.  
 
The genes associated with the hypomethylated DMFs are as follows: Complexin-1 (CPLX1), 
Diacylglycerol Lipase Beta (DAGLB), KDEL Endoplasmic Reticulum Protein Retention 
Receptor 2 (KDELR2), Family With Sequence Similarity 102 Member A (FAM102A), Calcium 
Release Activated Channel Regulator 2A (EFCAB4B), N-Acetyl-Alpha-Glucosaminidase 
(NAGLU), Adenomatosis Polyposis Coli Down-Regulated 1 (APCDD1), Polypyrimidine Tract 







coding gene: Relationship to TSS: 
4:793929 - 794143 -0.1786 CPLX1 Within intron 2 
7:6511106 - 6511153 -0.1000 DAGLB/KDELR2 Within an intron of the gene body 
9:130768316 - 
130768366 -0.4308 FAM102A ~26 kb upstream 
12:3862528 - 3862582 -0.1664 EFCAB4B (CRACR2A) Within promoter 
17:40683608 - 
40683711 -0.2329 NAGLU 
Within promoter 
flank; 4.2 kb upstream 
18:10271529 - 
10271568 -0.2000 APCDD1 ~183 kb upstream 
19:789109 - 789181 -0.3608 PTBP1 ~8 kb upstream 




There were five hypermethylated DMFs, with a difference of 0.19-1.00 (Table 3.8). Four of 
these are situated within the gene body of their respective genes, and one is intergenic. 
Table 3.8: Differentially methylated fragments which show hypermethylation in ADPKD 
Fragments are identified by their location within the chromosome and the nearest protein-coding gene. 
The difference in methylation is calculated by subtracting the methylation score of non-ADPKD from 
that of ADPKD. The relationship to TSS refers to the distance between the fragment location and the 
transcription start site of the nearest protein-coding gene.  
 
These genes associated with the hypomethylated DMFs are: Transmembrane Protein 18 
(TMEM18), Golgi To ER Traffic Protein 4 (GET4), KDEL Endoplasmic Reticulum Protein 
Retention Receptor 2 (KDELR2), DNA Cross-Link Repair 1C (DCLRE1C) and 
Transmembrane Serine Protease 6 (TMPRSS6). 
 
As the function of these fragments is not limited to the nearest protein coding gene, in silico 
analysis was performed with GenHancer [150] to predict if they play a regulatory role, 
potentially to genes not located linearly across the genome (Table 3.9). Five of the DMFs were 








coding gene: Relationship to TSS: 
2:771624 - 771728 0.3425 TMEM18 ~94 kb upstream 
7:922176 - 922249 0.5226 GET4 Within intron 9 
7:6495310 - 6495378 0.2208 KDELR2 Within an intron of the gene body 
10:14979087 - 
14979136 1.0000 DCLRE1C 
Within an intron of the 
gene body 
22:37499386 - 
37499523 0.1810 TMPRSS6 





Table 3.9: Predicted regulatory roles of DMFs 
DMFs were analysed to identify any associated enhancer elements (GenHancer). DMFs below 
contained at least one regulatory element. 
 
3.3 Expression of DMF-associated genes in ADPKD 
Eight of the DMFs found in this study were investigated with qPCR for gene expression 
analysis in ADPKD tissue isolated from five individuals (Table 3.1). Both NAGLU and GET4 
demonstrated significant differential expression between ADPKD and non-ADPKD tissue 
samples (Fig. 3.7). 
 
Figure 3.7: Expression of DMF-associated genes NAGLU and GET4 
Change in expression (Δ) was reported from qPCR data, using reference genes B2M and EEF1A1. Both 
genes had a statistically significant reduction in ADPKD (p = 0.0357, Mann-Whitney U Test). Bars 
indicate mean expression values ± SD. 
 
Chromosome coordinates: Closest Protein-Coding Gene: 
Differential 
Methylation: Predicted Enhancer: 
7:922176 - 922249 GET4 0.5226 PRKAR1B, DNAAF5 
9:130768316 - 130768366 FAM102A -0.4308 LOC101929314,  FAM102A,  PIP5KL1 
12:3862528 – 3862582 EFCAB4B -0.1664 CRACR2A, TULP3 
17:40683608 – 40683711 NAGLU -0.2329 TUBG2, NAGLU, RABC5C, HSD17B1, MLX, BECN1 












































Correlation studies between gene expression and DMF methylation values did not show a 
statistically significant correlation in NAGLU and the DMF (17:40683608 – 40683711), 
however they did identify a strong correlation between the expression of GET4 and the 
methylation of the DMF (7:922176 – 922249) (Fig. 3.8). 
 
 
Figure 3.8: Correlation of DMF methylation and gene expression 
Spearman’s rank correlation was used to determine the correlation between the methylation and 
expression of DMF-associated genes NAGLU and GET4 in ADPKD (red) and non-ADPKD (blue) 
kidney tissue. This association was statistically significant in GET4.  
 
3.4 PKD1 in ADPKD tissue 
PKD1 is the gene most attributable to ADPKD. Previous investigations of PKD1 have 
identified both increased and decreased expression of the gene to be associated with ADPKD, 
and published methylation analysis has identified the correlation between hypermethylation of 
the PKD1 gene body and our reduction of PKD1 expression. We decided to investigate this 
within our samples of kidney tissue, using fragments associated with PKD1 in the RRBS data. 
 
3.4.1 Methylation surrounding the ADPKD-associated gene PKD1 
There were 52 fragments in the analysed fragment group that were associated with PKD1, 
spanning a 31,060 bp region (Fig. 3.9A). None of these fragments were classified as DMFs, as 















r =  0.7906
p = 0.1333




















although there were some differences in methylation between the two groups, the p value 
calculated to account for multiple comparisons was greater than 0.05. 
 
The 11 fragments at the 3’ end of PKD1 (spanning 16:2164268-2170942) demonstrated a 
difference in methylation between 0.02-0.12 in the two tissue groups is visible as a different 
pattern of methylation on the histogram (Fig 3.9B). Additionally, the methylation of ADPKD 
samples varied greatly, lowering the power and therefore the ability to identify this region as 
being statistically differentially methylated. Another irregularity between the samples was a 
fragment in this middle of the analysed PKD1 region, for which the non-ADPKD methylation 
value is much lower. 
 
 
Figure 3.9: Coverage of PKD1 with RRBS fragments 
A) There were 52 fragments analysed between the two tissue groups. The fragments cover a 31 kb region 
from intron 1 to exon 46. B) The median methylation score at each fragment in ADPKD (red) and non-
ADPKD (blue) groups. Methylation between the two disease states is largely consistent. There is a small 
amount of hypermethylation at the 3’ end of the gene, and an additional point of differential methylation 
at 16:2147611-2147671 as indicated by green arrows. 
 
3.4.2 Expression of PKD1 in ADPKD 
In order to assess if these modest methylation differences between ADPKD and non-ADPKD 
tissue translate into functional differences in the expression of the disease-related gene PKD1, 






The three non-ADPKD tissues were used as a reference on which to normalise the data from 
five ADPKD samples, which included tissue samples from the four patients in the above RRBS 
analysis, as well as a sample from an additional ADPKD patient. 
 
The expression of PKD1 was tightly regulated in non-ADPKD tissue, with all samples yielding 
very similar Cq values. However, in ADPKD samples, the expression of PKD1 varied widely 
between samples. Overall there was a 0.504 increase in ADPKD tissue (p = 0.036) when 
compared with non-ADPKD tissue (Fig. 3.10). Of the ten RRBS fragments located within 
PKD1 with a nominal p < 0.05, the methylation of five showed correlation with PKD1 gene 
expression (Supplementary Table H.1) 
 
Figure 3.10: Expression of PKD1 
The change in PKD1 expression (Δ) is reported relative to the reference genes B2M and EEF1A1. PKD1 
had a statistically significant reduction in ADPKD patients (p = 0.0357, Mann-Whitney U Test). Bars 
indicate mean expression values ± SD. 
 
3.5 miRNA in ADPKD 
There are three microRNA within the promoter and gene body of PKD1: miR-1225, miR-3180 
and miR-4516. Because miRNAs are involved in the post-translational regulation of gene 

























expression of these genes were altered in ADPKD tissue. Five ADPKD tissue samples and three 
non-ADPKD samples were analysed, using the TaqMan Advanced miRNA Assay kit as per 
Section 2.4.5, with expression normalised to the reference gene miR-191-5p. 
 
The analysis of these miRNA indicated that both miR-1225 and miR-3180 have very little 
expression in the kidney, and there is no evidence that the expression is altered in ADPKD. 
Preliminary analysis of miR-4516, however, demonstrates varied expression in ADPKD 
(Fig. 3.11). 
 
Figure 3.11: Expression of miR-4516 
Change in relative expression (Δ) between ADPKD and non-ADPKD tissue was reported from qPCR 
data, using reference gene miR-191-5p. There was no significant change in expression in ADPKD. 
 
Two of the ADPKD samples (ADPKD 07, D) had reduced levels of miR-4516 expression, 







The defining feature of ADPKD is the number of cysts that develop within the kidneys. It is 
hypothesized that these all arise from individual molecular events. To investigate whether 
changes seen in the ADPKD kidney are universal within unique ADPKD cysts, the methylome 
of ADPKD cysts were analysed. Reduced representation bisulfite sequencing (RRBS) libraries 
were generated from the walls of unique cysts from a nephrectomized ADPKD kidney. 
 
4.1 Source material 
4.1.1 ADPKD cell lines 
Cell lines WT 9-7 and WT 9-12 were grown from passage 16 and 25, respectively. They were 
cultured on collagen coated plates as per the protocol in section 2 for 10 days. WT 9-12 was 
noted to be slightly more confluent than WT 9-7, but both cell cultures were polygonal in 
appearance, which is typical of kidney epithelia [151] (Fig. 4.1).  
  






Figure 4.1: Cultured immortalised ADPKD cells 
WT 9-7 (A) and WT 9-12 (B) were grown on collagen coated plates for ten days. WT 9-12 was observed 
to be more proliferative than WT 9-7. 
 
4.1.2 Isolated ADPKD cyst walls 
Sections of cyst walls were collected from the right kidney of patient “ADPKD D”. This 1,184 g 
kidney had been preserved in neutral buffered formalin (NBF) for one week prior to dissection. 
Although the colour of tissue changes following formalin preservation, it appeared to contain 
adipose tissue within the centre of the kidney (much like the adipose tissue observed in the left 
kidney in Chapter 3). Because of the manner in which the kidney had been removed, spatial 
proximity of cyst samples was not recorded. 
 
4.1.3 Generation of RRBS libraries 
Because cyst wall samples were so small, very low quantities of DNA were eluted from the 
samples, and thus libraries were generated from 0.5 µg of DNA. During library preparation 
many of these samples had high amounts of adaptor contamination (Fig. 4.2) for which they 
required an additional round of size selection with bead purification. Ten cyst walls were 







Figure 4.2: Bioanalyzer trace before and after adaptor clean up 
(A) ADPKD Cyst 3 had adaptor contamination (peak at 129 bp as identified with arrow). The RRBS 
library is between 178- 323 bp with the highest peak at 199 bp. (B) The adaptor contamination of the 
Cyst 3 RRBS library was reduced following bead purification. 
 
The mapping, bisulfite conversion and quality scores of the RRBS libraries produced from the 
cyst samples were comparable to those produced from whole tissue samples that had been 
produced from the 0.5 µg DNA RRBS protocol. These samples all had lower genome coverage 








Table 4.1: Genome coverage and efficiency of RRBS libraries 
Seven of the libraries were prepared with previously published RRBS protocol requiring 2.5 µg of input 
DNA. The remaining 12 libraries were prepared with the modified 0.5 µg protocol. Libraries prepared 






No. of alignments with 














WT 9-12 2.83E+07 1.80E+07 63.60% 3.66E+08 





Non-ADPKD G 3.50E+07 2.34E+07 67.00% 4.92E+08 
Non-ADPKD H 4.15E+07 2.83E+07 68.30% 5.93E+08 
ADPKD 07 4.69E+07 3.13E+07 66.70% 6.38E+08 
ADPKD 08 5.72E+07 3.78E+07 66.20% 8.06E+08 
0.5 
ADPKD 05 1.86E+07 1.01E+07 54.20% 2.01E+08 
ADPKD D I 9.95E+06 4.75E+06 47.70% 6.88E+07 
ADPKD D II 1.43E+07 7.26E+06 50.80% 1.31E+08 
ADPKD D III 1.42E+07 7.70E+06 54.20% 1.37E+08 








Cyst 2 3.25E+07 1.71E+07 52.50% 3.11E+08 
Cyst 3 2.11E+07 1.14E+07 54.20% 2.31E+08 
Cyst 4 8.93E+06 4.65E+06 52.00% 5.78E+07 
Cyst 5 1.93E+07 8.20E+06 42.50% 1.57E+08 
Cyst 6 3.88E+07 1.88E+07 48.40% 3.52E+08 
Cyst 7 2.84E+07 1.11E+07 39.10% 1.97E+08 
Cyst 8 1.43E+07 6.15E+06 43.00% 1.07E+08 
 Median 2.84E+07 1.44E+07 54.20% 2.76E+08 
 
 2.5 µg Median 4.15E+07 2.59E+07 66.20% 5.50E+08 
 





4.1.4 Concordance of sequencing data 
This analysis created RRBS libraries from three DNA sources: fresh-frozen tissue, formalin-
fixed tissue and immortalised cell lines. Because these tissues undergo different chemical 
processes which have the potential to alter epigenetic tags and affect the quality of DNA, it is 
important to check that the sequencing data is concordant. To do this, the correlation 
coefficients between the libraries were calculated for the cell lines (Table 4.2) and cysts 
(Table 4.3), as visualised in Fig. 4.3. 
 
Table 4.2: PCC of cell line RRBS libraries 
Mean PCC are calculated from individual paired correlation values; full table in Appendix H. 
 WT 9-7 WT 9-12 
ADPKD Tissue 
ADPKD 05, 07, 08, D I, D II, D III 0.944 0.890 
Non-ADPKD Tissue 
Non-ADPKD E, G, H 0.954 0.891 
Cell Lines 
Correlation between two cell lines 0.935 
 
Table 4.3: PCC between various ADPKD libraries 
Mean PCC are calculated from individual paired correlation values; heatmap of data in Fig. 4.3. 
 Mean PCC value 
ADPKD Tissue 
ADPKD 05, 07, 08, D I-III 0.980 
Biological Replicates 
ADPKD D I-III 0.979 
ADPKD Cysts 
All analyses between Cysts 1-8 0.987 
Non-ADPKD Tissue 
Non-ADPKD E, G, H 0.987 
 
The cell lines show a low correlation with tissue samples (both ADPKD and non-ADPKD 




biological replicates (cell lines derived from the same patient). These data indicated that 
immortalised cell lines would not be suitable for this research as they did not resemble kidney 
tissue. The formalin-fixed samples had consistent correlation with ADPKD tissue and were 







Figure 4.3: Heatmap of correlation between RRBS libraries 
PCC values plotted on a heat map to illustrate relative concordance. (A) All 19 RRBS libraries plotted. 
The immortalised cell lines had significantly lower concordance than any of the tissue-sourced libraries. 
(B) The RRBS libraries, excluding the cell lines. Correlation varied between samples, but non-ADPKD 
samples cluster together as they have the lowest concordance in this set of data. Data extracted from 









4.2 Clustering analysis 
4.2.1 Unsupervised hierarchical clustering of RRBS libraries 
Using the same pool of common analysed fragments which were used to calculate PCC 
(n = 38,139), unsupervised hierarchical clustering was performed on all libraries prepared in 
this research (Fig. 4.4). 
 
Figure 4.4: Unsupervised hierarchical clustering of all RRBS libraries 
Clustering was performed on all common analysed fragments between all 19 RRBS libraries 
(n = 36,824). Cell lines (grey) cluster independent of all tissue samples. There are varying degrees of 
relatedness between non-ADPKD (blue) and ADPKD (red) tissue. The biological replicates from patient 
ADPKD D (whole tissue and cyst) are a darker red, and cluster into two groups.  The ‘complete’ method 
of clustering was used. 
 
As expected, the cell lines WT 9-7 and WT 9-12 clustered independently and at the highest 
































































































The non-ADPKD tissue samples E, G and H were clustered together, as were the whole tissue 
samples 05, 07 and 08. Samples from patient ADPKD D were seen to cluster into two distinct 
groups. The technical replicates ADPKD D II and III had clustered very closely together, 
confirming the precision of the RRBS analysis. They were within a cluster that contained four 
of the eight cyst samples (cysts 2, 3, 4 and 6). The other ADPKD D whole tissue sample was 
in a distinct cluster with the remaining cysts (1, 5, 7 and 8). 
 
Additionally, when hierarchical clustering was performed on solely the ADPKD cyst samples 
(based on common fragments between only these libraries) the same clustering pattern was seen 
(Fig. 4.5). 
 
Figure 4.5: Unsupervised hierarchical clustering of single cyst libraries 
Clustering was performed on common analysed fragments between all eight cysts (n = 39,805). The 
‘complete’ method of clustering was used. 
 
4.2.2 Consensus clustering of ADPKD cysts 
The individual ADPKD cyst libraries were analysed with the program ConsensusClusterPlus 
(Fig. 4.6), which is an algorithm that assists in defining the suitable cluster count in an 


































Consensus matrices were produced for each k value (where k is the predetermined number of 
clusters). Under each cluster, the more strongly items cluster together, the higher the consensus 
is (illustrated by depth of blue). Plots k = 3 and k = 4 have the strongest consensus matrix, with 
no overlaps between the determined clusters. However, in k = 4, there is not as strong consensus 
between items in the same clusters, therefore k = 3 is the stronger candidate for accurate 
clustering. k = 6 also has strong consensus between clusters, but the member count of each 
matrix shown in this plot includes only one sample, therefore this is not an informative 
clustering strategy. 
 
The cumulative distribution function (CDF) plot displays the distribution of consensus for each 
k value. In this analysis, sample k = 3 indicates the maximum stability: k = 2 has a much lower 
CDF value, and k = 4, 5 and 6 demonstrate that further divisions are equivalent to random picks. 
 
The delta area graph shows the relative change in area under the CDF curve, illustrating the 
relative increase in consensus between clusters. In this plot, there is no appreciable increase in 
consensus after k = 4. 
 
The cumulation of this analysis shows that the data clusters well into three groups. While there 
is no appreciable increase in consensus after k = 4, the k = 4 consensus matrix shows that two 
of the clusters contain only one cyst, therefore this would not be an informative division of 
clustering. In fact, the tracking plot demonstrates that one of the clusters from k = 3, light green, 






Figure 4.6: ConsensusClusterPlus matrices 
The ConsensusClusterPlus algorithm visualises the consensus values between samples (between 0 and 
1). Consensus Matrices with clustering dendrograms are generated for each k value. k = 3 is the ‘cleanest’ 
consensus matrix (A) and demonstrates the most appropriate maximum stability on the CDF plot (B). k 
= 4 has the least increase in consensus (C) but as two of its clusters contain individual samples (D) it is 













4.3 Global methylation in ADPKD cysts 
The cyst samples were derived from tissue from patient ADPKD. Previous comparison of the 
median methylation of whole tissue samples had identified that this patient’s genome was 
significantly hypomethylated compared to other samples in this analysis. The global 
methylation of each RRBS library used in the analysis of ADPKD tissue (excluding cell lines) 
was plotted (Fig. 4.7A). 
 
This shows samples ADPKD D I, II and III had a considerably lower median methylation than 
other whole tissue counterparts, and that the median was also lower in cyst samples, particularly 
cysts 4 and 8. However, when the global methylome of each sample was plotted based on only 
the common analysed fragments between the 17 libraries (n = 36,888), the median value of 
methylation was very similar across all samples (< 0.1) (Fig. 4.7B). This suggests that the 
proportion of genomic fragments analysed was different in these hypomethylated libraries. To 
investigate this, the proportion of genomic elements in each library were calculated (Fig. 4.8) 






Figure 4.7: Global methylation of all RRBS libraries 
The median methylation of each library is marked by the bar, interquartile values are represented by the 
bars, whiskers extend to minimum and maximum values. A) The total number of sequenced fragments 
in each library, n ranges from 51,805 – 397,796. B) Global methylome of RRBS libraries, based only 

























































































































































































































Figure 4.8: Proportion of genomic elements in RRBS libraries 
The non-ADPKD reference library, ADPKD D III and Cyst 4 libraries demonstrate that the libraries 




Figure 4.9: Methylation of genomic elements in RRBS libraries 
The non-ADPKD reference (blue), ADPKD D III and Cyst 4 libraries (red) were analysed at each 
genome feature. This demonstrates that the low methylation values are not due to the overrepresentation 
of promoter fragments (which are typically hypomethylated). 
 
From this it is apparent that while the hypomethylated libraries (i.e. ADPKD D, Cyst 4) have a 
higher proportion of promoter coverage, this is not (the sole) contributor of the hypomethylation 

















lower median methylation values (and therefore, the finding in Chapter 3 than ADPKD is 
globally hypomethylated is valid). 
 
When ADPKD cysts were paired to the (grouped) non-ADPKD methylome by common 
analysed fragments, global methylation patterns were plotted (Fig. 4.10). In five of these cysts, 
the median methylation is higher than that of the non-ADPKD group. This is in contrast to the 
previously generated data we have produced from whole tissue, which demonstrates 
hypomethylation in ADPKD. Of the remaining three cyst libraries, one demonstrates 
hypomethylation and the other two have median methylation equal to that of non-ADPKD. In 
seven of the eight cysts, however, the interquartile range in ADPKD trends lower than that of 
non-ADPKD. 
 
Figure 4.10: Global methylation of paired non-ADPKD and cyst RRBS libraries 
Cyst libraries (red) were paired against the non-ADPKD reference genome (blue), and the methylation 
values of only the common analysed fragments in each pair are plotted on the violin plot. Five of the 
cyst libraries (1, 5, 6, 7 and 8) are statistically hypermethylated, as the median value (represented by the 



















4.3.1 Methylation status of previously identified DMFs in cysts 
The specific DMFs identified within the whole ADPKD tissue were investigated in the cyst 
data by performing ANOVA analysis between the three non-ADPKD samples and eight cyst 
samples in order to provide consistent comparisons between the groups. Methylation scores 
were compared across three tissue types: non-ADPKD tissue, ADPKD whole tissue and 
ADPKD cysts. Of the 13 DMFs, 11 had coverage in at least two of the eight cysts; there was 
no coverage in the cysts at the CPLX1 and TMPRSS6-associated fragments. 
 
Eight of these fragments were determined to be significantly differentially methylated in the 
cysts (FDR-adjusted p < 0.05). The remaining three fragments (KDELR2, DCLRE1C and 
APCDD1-associated fragments) did not show the same difference in methylation as seen in 










Figure 4.11: Methylation of the whole tissue-identified DMFs in cyst libraries 
Statistical significance between non-ADPKD libraries and ADPKD cysts was carried out with ANOVA. 
Eight of the DMFs identified in ADPKD whole tissue (Section 3.2) were significantly differentially 
methylated in the group of individual ADPKD cysts. FDR-adjusted p values: * = p < 0.05, ** = p < 0.01, 








There are very few published data on DNA methylation in ADPKD. This study set out to 
identify the global methylation changes associated with ADPKD, and to identify changes within 
specific regions that may be involved in the disease. Additionally, it set out to determine if the 
analysis of whole tissue from ADKPD kidneys is able to interrogate the ADPKD methylome, 
or if unique changes occurred within individual ADPKD cysts that cannot be mapped by bulk 
analysis. 
 
5.1 Quality of data 
The RRBS libraries generated in this analysis demonstrated high Phred scores across the whole 
read lengths, which shows that the base calling was accurate, and that the methylation data 
observed was likely to accurately represent the methylome of the samples analysed. 
 
RRBS has the capacity to cover ~4 million CpG sites across 647,902 fragments [144, 152], 
however, historically in experimental protocols it is typical to yield approximately 340,000 or 
fewer fragments [153]. This is because the established statistical analysis techniques in our 
group require there to be coverage at least ten reads deep on fragments containing two or more 
CpG sites. While these techniques reduce the quantity of fragments available for analysis, it 
reduces the likelihood of sequencing errors. 
 
Bisulfite conversion was > 98% in the RRBS libraries, which is approximately the level 
expected based upon previous studies using this methodology [153] and indicates that the 
protocol was carried out successfully. The samples prepared from 0.5 µg of DNA had low 




mapping efficiencies (< 60%), which is lower than expected for libraries prepared with this 
protocol. This may have been due to the reduction in DNA input to the modified protocol. The 
PCR amplification process typically results in the overrepresentation of adaptor dimers [154] 
which need to be removed with additional bead amplification, and two of the ten cyst samples 
originally collected could not be sequenced due to low DNA concentrations after the final 
elution. A suspected reason for this is that the protocol in this study used PfuTurbo DNA 
Polymerase for PCR amplification of the library. The methodology has since been updated in 
our laboratory to replace Pfu with KAPA Polymerase, which has shown an increased efficiency 
of library amplification during the PCR stage of the protocol. The reason for this increased 
efficiency is unclear as both polymerases are designed for high-fidelity PCR.  
 
Another factor affecting the mapping efficiencies is the source material itself. The majority of 
samples with low mapping efficiencies and genome coverage were the individual cyst samples, 
which were very small sections of tissue dissected from neutral buffered formalin-fixed tissue. 
Formalin influences DNA solubility, resulting in lower yields of DNA than from fresh tissue 
[155]. It is also known to contribute to DNA fragmentation, resulting in a reduction in the 
quality of the yield [156, 157]. The kidney used for this collection had been treated in formalin 
for seven days prior to our access to the tissue, therefore the DNA was almost certainly 
degraded to some degree. 
 
5.2 The ability of RRBS to assess the methylome of kidney tissue 
RRBS is a reproducible and validated research technique for assessing the genome wide 
methylation of samples of DNA [152, 158-161]. The reliability of the methodology in this study 




the RRBS library coverage largely varied between samples, the PCC was calculated from the 
pool of common fragments, to avoid any biases due to sampling.  
 
Using parameters previously described [149], a PCC 0.95-0.99 suggests there is substantial 
concordance between the data, and PCC > 0.99 is almost perfect concordance. It is expected 
that technical replicates (ADPKD D II and III) should have a PCC approaching 0.99; this was 
seen in this study as the technical replicates had a 0.993 concordance value. This illustrates that 
the protocol and sequencing method was accurate in reporting the methylation of the tissue. 
 
Sample ADPKD D I was a biological replicate of the two above samples, as it was prepared 
from an independent tissue section from the same patient kidney. The PCC between biological 
replicates was 0.971 (comparison between I and II) and 0.970 (comparison between I and III). 
While still indicating a substantial level of concordance between the samples, the 3% variation 
in these samples shows there is some heterogeneity between different sections of the ADPKD 
kidney. Each tissue sample was selected from different sites from the kidney therefore the exact 
cellular makeup of each tissue section is likely to be different. 
 
Surprisingly, the biological replicates above have a slightly lower correlation than the 
correlation between unrelated ADPKD samples (mean PCC = 0.983). This may mean that 
ADPKD D I tissue has a different composition of cells compared to the other ADPKD tissue 
samples. However, this difference is still relatively small, as the methylomes still have 
substantial correlation, and additional biological replicates of the other ADPKD samples (if 





The non-ADPKD samples are also closely related to each other, with a mean PCC between 
pairs 0f 0.987. The small amount of variance between samples is likely because each patient 
has their own unique methylation. An inter-individual study found a range of concordance 
between DNA methylation of individuals was between 0.93 and > 0.99, dependent on the tissue 
type (renal tissue was not reported) [162]. The non-ADPKD samples suggest that 
approximately 98% of the methylome is required for all kidney cells and remains invariant. 
 
It was noted that the immortalised cell lines originating from ADPKD single cysts (WT 9-7 and 
WT 9-12) displayed different methylation patterns than any of the kidney samples. According 
to the previously mentioned parameters [149], between 0.90 – 0.95 is moderate concordance, 
and PCC < 0.90 is poor concordance. Cell line WT 9-7 had a mean PCC of 0.937 and WT 9-12 
had a mean PCC of 0.882. While these cells are morphologically characteristic of epithelial 
cells (polygonal [163]) and characteristic of ADPKD [141], the immortalisation process may 
have altered the epigenetic makeup of the cells in order to evade senescence. There is 
experimental evidence to suggest that SV40 immortalisation of the cell lines means they cannot 
be relied upon to show methylation changes [164], and DNA methylation progressively changes 
with increased passages [165, 166]. Investigation of paired primary cells from primary and 
metastatic tumours shows no change in global methylation profiles [159], suggesting the 
biggest factor in the observed discrepancy in our data is immortalisation. 
 
Additionally, there was a discrepancy between the two cell lines themselves. As they were from 
the same patient, they may be expected to have a high level of similarity, however, the 
concordance between the two cells is 0.951. The origin of the cells may contribute to global 
methylation differences between the samples; the cell line WT 9-7 has been characterised as 




distal tubules [141]. Another possibility is that the immortalisation process has caused the 
methylomes of these replicating cell lines to be dysregulated, or the number of passages the 
cells have undergone prior to arriving in our laboratory may have contributed to changes in 
DNA methylation. While the exact cause is unclear, it does show that the cell lines no longer 
accurately portray the in vivo ADPKD methylome. 
 
The ADPKD single cyst RRBS data were highly concordant with each other (mean 
PCC = 0.987). The cysts were biological replicates of each other, and biological replicates for 
the whole tissue samples ADPKD D I, II and III. The concordance between the cysts was higher 
than the concordance between the whole tissue biological replicates (mean PCC = 0.978). As 
alluded to above, the whole tissue samples are comprised of many cell types, and likely multiple 
cysts. The cell types of the kidney comprise of nephrogenic cells (renal tubules are formed of 
epithelial cells) [167] and the stroma, which includes fibroblasts and smooth muscle [168]. The 
individual cyst samples, however, were dissected with the aim of reducing the heterogeneity of 
the samples, both by reducing the number of cysts in each sample, and by reducing the 
proportion of stromal cells. Therefore, it could be concluded that the individual cyst samples 
better represent cystic ADPKD kidney tissue.  
 
5.3 Hierarchical clustering 
Hierarchical clustering (Fig. 4.4) of the common analysed fragments of all 19 libraries 
concurred with the correlation and variation values seen above. The immortalised cell lines 
WT 9-7 and WT 9-12 clustered the furthest away from all other RRBS libraries. As this cluster 
was so dissimilar to the remaining tissue samples, this supported the exclusion of immortalised 





The non-ADPKD tissue clustered separately from the ADPKD samples, demonstrating a 
difference in methylation based upon phenotype. The whole tissue samples 05, 07 and 08 were 
in one cluster, and the samples from patient ADPKD D (three whole tissue samples and eight 
individual cysts) were split into two clusters.  
 
Technical replicates clustered tightly together, along with four of the cyst samples. The 
remaining whole tissue sample and four cysts were in an independent cluster. This suggests that 
there is some level of heterogeneity within patient ADPKD D to cause the splitting of clusters. 
One possible explanation for this is that these samples – particularly the individual cell lines – 
come from cysts that have originated from different cell types. It is known that cysts can arise 
from any region of the nephron [5], so it is possible that the characteristics of the originating 
tubule are preserved in the methylome.  
 
However, there are no data on the precise origin of each sample (due to the distorted nature of 
the ADPKD kidney and limited amount of tissue for immunohistochemistry staining), and there 
are lots of variables in the collection of cystic tissue (such as cyst size) so this hypothesis cannot 
be followed up in the present tissue. Furthermore, tubule origin is unlikely to contribute to the 
difference seen between whole tissue samples, as each tissue sample likely contained a more 
than one cyst which may have originated from different regions of the nephron.  
 
The deviation of methylation patterns in the clustering analyses could alternatively indicate 
independent pathways of DNA that might relate to the somatic mutation or change that initiated 
cyst formation. Previous data on prostate cancer has used DNA methylation alongside copy 
number data to map the unique clonal evolution pathway of tumours [169]. A similar analysis 




provide a tempting method of investigating cystic clonal development and intra individual 
variation, however the discrepancies of gene dosage in these models (Table 1.1) and differences 
between PKD1 and Pkd1 sequences indicate that this data may not accurately reflect human 
ADPKD mechanisms. 
 
5.4 DNA methylation analysis of whole ADPKD tissue samples 
5.4.1 Methylome-wide sequencing in ADPKD tissue 
The median methylation values of fragments in the libraries ADPKD 05 and D were 
significantly lower than the other ADPKD and non-ADPKD libraries, with reduced lower 
quartile methylation values. It was unclear if this was a biological feature of the two ADPKD 
libraries, or if there was an underlying methodology difference. These two whole tissue samples 
were generated by myself using the low-DNA input methodology, while the other five whole 
tissue samples were generated by Michael Bates with five times the amount of starting material. 
The data was exhibited across a variety of genomic factors, such as genomic elements and CpG 
island features (Appendix G), which revealed the difference in median methylation was 
consistent across investigated regions.  
 
Additionally, when all the kidney tissue libraries were compared at only the common analysed 
fragments (n = 36,824; Fig. 4.7), all libraries now had a much lower and similar median 
methylation value, in line with the least methylated library (Cyst 4). This suggests that the 
lower-coverage libraries had a bias to generate sequences for unmethylated (or low methylated) 
fragments. As Supplementary Fig. G.1 shows, the reduced median methylation of ADPKD D 
tissue did not influence the overall global hypomethylation pattern seen in ADPKD, as this 




influence the interpretation of the methylation data seen here but do provide limited power for 
a substantial analysis. 
 
Figure 4.7 indicates that the libraries generated from low-DNA input had lower median 
methylation even when adjusted for common analysed fragments only. These data, combined 
with the histograms in Appendix G (Supplementary Fig. G.2), suggest the reduced DNA 
methodology has generated libraries with smaller fragments, concomitant to the reduction of 
median methylation. This is further discussed in Section 5.9.3. 
 
5.4.2 Genome-wide methylation in ADPKD tissue 
When the RRBS methylome is assessed by calculating the median methylation of all 345,711 
fragments across the two tissue groups, the ADPKD genome has a methylation score 0.02 (2%) 
lower than the non-ADPKD genome. This difference in methylation is consistent across all 
genomic elements (Fig. 3.4). The Wilcoxon rank sum p value was < 2.2E-16 in all of these 
comparisons, so the value reported here is highly statistically significant and unlikely to be due 
to random chance. As ADPKD D has shown considerably lower methylation than the other 
samples in the analysis, the comparison between tissue groups was repeated excluding sample 
D (Supplementary Figure G.1). The difference between tissue groups was still 0.02, which 
confirmed that the low median methylation of sample D was due to the fragments in the 
ADPKD D genome originating from largely low-methylated fragments, as demonstrated in 
Section 5.4.1. 
 
Although there was reduced coverage in ADPKD D compared to the other samples, this sample 
was left in the whole tissue analysis as it added strength to the ANOVA between ADPKD and 





Global hypomethylation is a feature commonly associated with cancer and is believed to initiate 
chromosome instability and activate oncogenes in tumour cells [129]. Some oncogenes have 
been demonstrated to be aberrantly expressed in ADPKD tissue, and overexpression of these 
genes is sufficient to cause cystic disease in mice [170-172]. However, no DMFs were 
identified within any oncogenes in our ADPKD tissue analysis. Genomic instability has been 
suggested as a feature of ADPKD, including the development of somatic mutations in one of 
the PKD genes in order to initiate cystogenesis [97]. A hypomethylated genome, as is 
demonstrated here, could be sufficient to create an environment where somatic mutation occurs 
at a higher rate than in healthy tissue. 
 
Despite this, it should be recognised that the amount of hypomethylation is only 0.02, or 2%. 
Global hypomethylation has been described in cancer, with studies reporting as much as 90% 
of the genome to be hypomethylated [173-176]. Thus, the 2% difference in methylation 
observed in our data is marginal, and so biological consequences, if any, arising as a result of 
this hypomethylation are unclear based upon the current understanding of global DNA 
methylation in cancer. 
 
Due to the ambiguities of single-nucleotide genome alignment, RRBS does not have extensive 
coverage of repetitive elements [177]. As repetitive elements are often characterised as being 
areas that harbour significant amounts of hypomethylation in cancer [178], it is possible that if 
there was more coverage at these repetitive elements they would also be hypomethylated in the 
ADPKD tissue, making the magnitude of hypomethylation potentially more pronounced than 
that seen in this analysis. Other methods of methylation analysis, such as an EPIC-array analysis 





These global methylation data are also contradictory to the only other analysis of global 
methylation in ADPKD. Woo et al. report that 91% of CpG methylation sites with differential 
methylation (dCMES) were hypermethylated in their analysis [139]. A direct comparison 
between the two analyses cannot be made, as the estimate by Woo et al. is made by analysis of 
only the dCMES and not the genome at whole. Furthermore, our analysis is the summation of 
all fragments in the analysis, regardless of the statistical significance of each fragment between 
the two groups. 
 
Woo et al. used the MIRA-Seq technique for the analysis of global methylation in their three 
ADPKD samples. MIRA-Seq pyrosequencing works by exploiting the affinity of two methyl-
binding proteins for methylated CpGs, thus resulting in a higher proportion of methylated 
fragments in the final analysis than would be reported using RRBS. Additionally, this protocol 
is less likely to cover methylated CpG islands [180], and as it is an enrichment-based 
methodology, it is more prone to errors in methylation estimation especially when samples have 
high copy number variation, such as that seen in cancer [181, 182]. 
 
A cost-effective sequencing alternative to whole genome bisulfite sequencing (which has not 
yet been applied to ADPKD), RRBS uses a restriction enzyme digest that targets CpGs due to 
the cut site of MspI which is located within a CpG (C^CGG), irrespective of methylation. This 
method has an advantage over enrichment sequencing methodologies, which have an affinity 
for methylated cytosines [183]. Additionally, this methodology allowed us to analyse a greater 
number of CpG sites across both tissue groups, at single nucleotide resolution: Woo et al. 
generated 1 million CpGs in non-ADPKD and 0.7 million in ADPKD compared to our 1.7 





Considering the different sequencing approaches, our data indicating global hypomethylation 
provide a more conservative estimate of the ADPKD tissue methylome (with some data 
suggesting this is variable across individual cysts). Our study has a number of strengths, 
including similar age-matched samples and single nucleotide resolution. 
 
5.5 Differentially methylated fragments 
We identified 13 fragments with significant differential methylation in ADPKD tissue. These 
regions have not been identified in the previously published DNA methylation research in 
ADPKD [139], although this paper did not publish a full list of all differentially methylated 
sites and therefore we cannot rule out a similarity between experimental findings. 
 
Thirteen is a relatively low number of loci to identify in an RRBS analysis. Woo et al. identified 
more regions in their 2014 paper using a different sequencing approach. It is possible that 
different methodologies contributed to the difference in quantity of DMFs. As mentioned above, 
MIRA-Seq analysis is based upon enrichment analysis, which is much more prone to errors 
[182] and does not have the same CpG resolution as RRBS. 
 
Another possibility for these differences is that the ANOVA test did not have sufficient power 
to identify additional DMFs due to the lower coverage in ADPKD libraries 05 and D I. This 
appears to be the result of using the adjusted RRBS methodology with reduced input amount 
of DNA (Section 5.2).  
 
Additionally, each patient may have a different methylation landscape due to other factors 




influencing or causing this pathology, and the DNA methylation seen is a consequence of, or a 
response to, these factors. As ADPKD is a heterogeneous disease, these factors could even 
differ between patients. Regardless of what causes the variation, this has led to higher 
FDR-adjusted p values which in turn renders a lot of the additional observed differences 
between the disease-state groups as statistically insignificant. 
 
There were more hypomethylated DMFs (eight) than hypermethylated (five). There was a slight 
enrichment of DMFs within intergenic regions and intron/exon regions, although due to the low 
number of total DMFs this limits the significance of any observed trends. 
 
5.5.1 Intergenic DMFs 
Five of the DMFs were located in regions outside of the protein-coding region (i.e. not within 
the promoter or gene body). As these fragments are as far as 183 kb from the nearest 
protein-coding gene, they provide tenuous links to the closest genes and thus only brief 
summaries of these gene functions and their potential roles in ADPKD are presented below. 
 
APCDD1 is an inhibitor in the Wnt signalling pathway, where increased expression has been 
associated with colorectal tumourigenesis [184, 185]. Hypermethylation of the APCDD1 has 
also been implicated the increased expression of the gene in osteosarcoma [186]. APCDD1 has 
shown expression in skin and fat tissue among others, but relatively low expression in kidney 
[187]. As previously described, the ADPKD tissue samples were noted to contain high levels 
of adipose deposits, particularly within the medullary regions and surrounding the external 
kidney walls. Therefore, the altered methylation value may be associated with the presence of 





There was methylation data available from five of the eight single ADPKD cysts for this 
APCDD1 fragment. These data were not as hypomethylated as the whole tissue samples, and 
ANOVA analysis did not find this fragment differentially methylated in the ADPKD cysts.  
 
The transcription repressor TMEM18 has various roles reported in literature, including neural 
cell migration and obesity [188, 189]. One possible link to its role in ADPKD tissue is that a 
2014 paper identified that the promoter methylation of TMEM18 and subsequent reduced 
mRNA levels were related to the deposition of visceral adipose tissue [190]. Much like 
APCDD1, the altered methylation associated with this gene may be linked to the presence of 
adipose tissue in ADPKD. 
 
FAM102A is a poorly characterised gene, believed to play a role in estrogen action [191]. There 
is very little evidence to connect it to ADPKD, with the exception that as it is a hormone-related 
gene, sex differences between the ADPKD and non-ADPKD tissue groups in this analysis 
(discussed further in Section 5.9.4) may cause the differences in methylation seen here, rather 
than disease itself. 
 
ZNF343 is ubiquitously expressed in all tissue as it is required for the regulation of gene 
expression in all cells [187]. It is important for nucleic acid binding, and there are no syndromes 
associated with it. Therefore, any role it may be playing specifically within ADPKD is unclear. 
 
PTBP1 is a translational regulator in the cell, involved in pre-mRNA and alternate splicing. 
Regulated by miRNA, expression of this gene is associated with several forms of carcinoma 
[192]. Like ZNF343, there is no clear connection to ADPKD for this gene. Additionally, PTBP1 




expression as PCR primers were readily available, however no difference was seen between 
tissue groups. While analysis of the single ADPKD cysts found the difference in methylation 
at this fragment to be statistically significant, there was a wide spread in the methylation of this 
fragment across the single cyst samples. This range of DNA methylation was not seen in the 
whole tissue samples. 
 
Both of the DMFs associated with FAM102A and PTBP1 were predicted to contain enhancer 
elements, supporting the belief that the genes closest to the DMFs themselves may not be 
significant to ADPKD, and instead suggesting that these genetic regions are associated with 
regulating other active pathways. 
 
5.5.2 Intragenic DMFs 
There were eight DMFs associated with protein-coding genes: within the promoter (two) or 
gene body (six). Although the function of all eight genes are discussed below, the involvement 
of these genes in ADPKD is unclear based upon methylome studies alone. Many of these genes 
also showed no change in RNA expression, and thus there is a possibility that the methylation 
changes are consequential of the disease state, not factors in the cystogenesis. 
 
5.5.2.1  CPLX1 
Essential for motor function, CPLX1 is a cytosolic protein involved in the exocytosis of synaptic 
vesicles. The product of CPLX1 binds to a SNAP receptor complex at the cellular membrane, 
allowing transmitter release when there is sufficient action potential (Ca2+) at the synapse [193]. 
Given that it is an important regulator in neural synapse, CPLX1 is expressed in the brain in 





The link between ADPKD and a neural protein is unclear, however one feature of this protein 
does relate to ADPKD: CPLX1 action is dependent on the concentration of Ca2+ - a molecule 
that has had a lot of attention in ADPKD as PKD2 is a calcium channel, and the concentration 
of Ca2+ is thought to be involved in cystic disease. 
 
A qPCR targeting this gene was performed on ADPKD tissue, however no difference was seen 
between non-ADPKD and ADPKD tissue. 
 
5.5.2.2  DAGLB 
Diacylgylerol lipase beta (DAGLB) is an enzyme that catalyses the hydrolysis of diacylglycerol 
to 2-arachinodonoyl-glycerol. This is the most abundant endocannabinoid in human tissue. This 
is the second of the genes associated with ADPKD that plays a role in neuronal signalling (the 
other being CPLX1). It is required for retrograde synaptic signalling at mature synapses – when 
post-synaptic cell bodies release a retrograde messenger to travel ‘backwards’ to bind at the 
axon terminal of a presynaptic neuron [194]. DAGLB is ubiquitously expressed in human tissue, 
with higher expression in some tissue types such as brain [187], but no noticeable renal 
significance. qPCR was not performed for this gene as primers with specificity to the gene 
sequence were not generated in the timeframe. 
 
In addition to retrograde signalling, DAGLB is required in the developmental period for axonal 
growth [195]. It is unclear why an axonal gene may be triggered in ADPKD, but the 
involvement of a gene required for development is not necessarily surprising, as the ADPKD 





5.5.2.3  KDELR2 
This gene is a member of the KDEL (Lys-Asp-Glu-Leu) receptor family, which recognises and 
binds to specific resident soluble proteins in the Golgi body, returning them to the lumen of the 
endoplasmic reticulum. The KDEL family is responsible for the retention of the luminal ER 
proteins, and combined, determine the specificity of this system. This is required within cells 
throughout the body, and thus KDELR2 is ubiquitously expressed in human tissue [187, 196]. 
 
The DMF 7:6511106 – 6511153 is located within the transcripts of both KDELR2 and the 
aforementioned DAGLB as these genes run on opposing strands. Additionally, both genes have 
multiple splicing transcripts. Therefore, it is possible that KDELR2 is not involved in ADPKD 
pathology, just close in proximity to a region of differential methylation. This is substantiated 
by gene expression observed by qPCR, which shows almost no difference between ADPKD 
and non-ADPKD tissue groups, with the exception of one outlier. Further evidence is found in 
the methylation of the data of the ADPKD cysts at this DMF, which do not show statistically 
significant methylation at this loci when compared to the non-ADPKD tissue. 
 
5.5.2.4  EFCAB4B 
Most commonly referred to in the literature as CRACR2A, EFCAB4B is a calcium release 
activated channel regulator, playing a key role in the store-operated entry of Ca2+ at the calcium 
release activated channel (CRAC), particularly in immune cells. CRAC channels require 
EFCAB4B and STIM1 binding to facilitate the flow of Ca2+ into the cell. STIM1 is located on 
the ER membrane and is sensitive to the stored Ca2+ within the ER, while EFCAB4B is a 






While broadly expressed in human tissue, the expression of EFCAB4B in kidney tissue is 
recorded as being low [187]. In ADPKD tissue no statistical difference in expression was seen 
(Appendix I). 
 
The EFCAB4B-associated DMF, which is located in the promoter has been identified to contain 
a binding site for the transcription factor EGR1 (Early growth response protein 1), which is 
required for development, and thought to be a tumour suppressor gene . EGR1 binds to genes 
irrespective of cytosine methylation [198], and plays a role in cellular growth, proliferation and 
death, possibly by means of regulating DNA damage [199]. 
 
Additionally, EFCAB4B is predicted to be an enhancer of the gene TULP3,  a negative regulator 
of a signalling transduction pathway which is recruited to primary cilia [200]. TULP3 regulates 
ciliary G protein-coupled receptor trafficking, and has only recently been reported as playing a 
regulatory role in ADPKD [201]. 
 
5.5.2.5  DCLRE1C 
As DCLRE1C was found to contain a DMF with 100% hypermethylation in ADPKD tissue, 
the potential functional role of this gene in PKD is very interesting. As a cross-link repair gene 
encoding the endonuclease ARTEMIS, it is involved in V(D)J recombination and DNA repair 
for double-stranded breaks. 
 
DCLRE1C may be required most within the immune system, given that it has higher levels of 
expression in the lymph nodes than other human tissues, and null DCLRE1C mutations causing 
ARTEMIS depletion result in severe combined immunodeficiency, and hypomorphic mutations 





The hypermethylated DMF in question is within intron 4 of DCLRE1C. According to the 
paradigm of methylation, this would be predicted to result in a sustained or increased expression 
of the gene. In contrast to patients with immunodeficiency above, the hypermethylation of the 
DCLRE1C gene body could increase the efficiency of ARTEMIS production, in turn increasing 
the efficiency of DNA repair. One possibility to explain why this may occur is that an increase 
in production of ARTEMIS could be an attempt to compensate for the genomic instability 
caused by the cystic disease. 
 
There was only methylation data from two ADPKD cyst samples at this site, which did not 
agree with the whole tissue data. While the cyst samples had more methylation than the non-
ADPKD tissue, they were not as methylated as the whole tissue, and were not statistically 
hypermethylated compared to the non-ADPKD tissue. It is unclear why these samples had such 
lower methylation when the whole tissue samples showed a strong binary pattern between the 
two disease states. There is no data at this site from the whole tissue from patient D (the same 
patient from which the cyst samples come from). 
 
Interestingly, when qPCR was performed with DCLRE1C primers, there was no significant 
difference in expression between the two tissue groups. With the exception of one ADPKD 
outlier with markedly higher expression, the expression of DCLRE1C was almost the same 
between ADPKD and non-ADPKD groups. As alluded to above, methylation of a gene body is 
theorised to support the ability of transcriptional mechanisms to interact with the gene to 




5.5.2.6  TMPRSS6 
TMPRSS6 encodes a protease found on the cell surface, required for matrix remodelling of the 
liver. TMPRSS6 hydrolyses type I collagen, fibrinogen and fibronectin as part of its role in 
degradation of the extracellular matrix. Additionally, TMPRSS6 plays a role in hepcidin 
production (which usually occurs within the liver). The expression of hepcidin is also tied to 
inflammation and infection; the reduction of hepcidin production is intended to restrict the iron 
available for pathogenic growth [203]. 
 
This gene shows highest expression in the liver, with very low expression in the kidney. 
TMPRSS6 is hypermethylated within the gene body in ADPKD tissue (across intron 1 and exon 
2), which could indicate that expression is increased, or at least stabilised, in ADPKD cells. 
The expression data generated in our laboratory showed no difference between the two groups. 
 
5.5.2.7  NAGLU 
The product of NAGLU is an enzyme that degrades heparan sulphate (HS) by hydrolysis. While 
ubiquitously expressed in human tissue, NAGLU is highly expressed in kidney tissue [204] 
[187]. Mutations in this gene result in the accumulation of HS, causing the disease 
mucopolysacchardosis type IIIB (MSP-IIIB), a neurodegenerative disorder [205]. Lower 
cellular temperature results in a higher activity of mutant enzymes in MSP-IIIB fibroblasts, 
although the mechanism controlling this is unknown [206]. 
 
This fragment was hypomethylated in the promoter in ADPKD tissue as evidenced by the 
analysis of two whole tissue samples. Although the ADPKD single cyst samples showed a 
slightly wider range in methylation at this fragment, the methylation was considered significant 





In preliminary expression analysis with qPCR, NAGLU was shown to be reduced (Δ = -0.68, 
p = 0.0357) in ADPKD (Fig. 3.7). Hypomethylation of a promoter is typically associated with 
the increased expression of the gene in question, so it is not as common to observe reduced 
gene expression (although this phenomenon has been described before [129]). There is no 
evidence to explain a direct relationship between the promoter of a gene and the subsequent 
reduction of gene expression, although it is plausible that the DMF methylation is leading to 
the overexpression of a repressor of NAGLU. The possible consequences of this are that the 
concentration of NAGLU in the cystic tissue is reduced, in turn increasing HS. HS regulates a 
wide range of biological activities, including development, angiogenesis (blood vessel growth) 
and tumour metastasis. It is a component of the extracellular matrix and is present on the surface 
of fibroblasts to allow cellular adhesion [207]. 
 
Additional methylation analysis on more ADPKD tissue samples should be performed to 
elucidate whether there is a significant correlation between the methylation of this promoter 
and the reduction of NAGLU mRNA. Further experimental research is also required to identify 
whether NAGLU expression is altered due to the presence of inflammatory responses, as 
previously proposed [208], or due to molecular mechanisms regulated by HS. The addition 
more samples in this test would also help elucidate whether these changes are correlated with 
the methylation of the gene promoter. 
 
5.5.2.8  GET4 
GET4 is a chaperone protein, ubiquitously expressed across all tested human tissue types [187]. 
This protein works in a complex alongside BAG6 and UBL4A, which regulate ER-associated 




damage signalling and cell death. GET4 and UBL4A are chaperones to BAG6, and the loss of 
both proteins is required to elicit resistance to cellular death. However, the combination of all 
three genes is required for optimal DNA damage response signalling, wherein the complex 
recruits BRCA1 to sites of DNA damage. 
 
Initial expression analysis of GET4 demonstrates a significant reduction in gene expression in 
ADPKD tissue (Δ = -0.941, p = 0.0357), with a strong negative correlation with the methylation 
of the DMF (r = -0.919, p = 0.0071). The GET4-associated DMF is strongly hypermethylated, 
with a difference of 0.52 between the non- and ADPKD tissue groups, a difference that has not 
been previously described in ADPKD. This fragment is located within the gene body (intron 
1), which is purported to strengthen the transcription of a gene, which is conflicting with the 
data presented here. However the fragment, while not defined as a promoter in this study (it is 
further than 1kb into the gene transcript), is at the 5’ end of the gene. It is typical that the 
methylation of the gene body enforcing gene transcription is typically seen towards the 3’ end, 
thus it is plausible that this methylated fragment is operating as a promoter with regulatory 
elements. 
 
Not only is there strong evidence to suggest a probable link between the methylation and 
expression of this gene in ADPKD, there has been a recent publication which identified another 
ADPKD-associated gene involved in ER-associated protein degradation (DNAJB11). 
DNAJB11 is another co-chaperone molecule in which novel mono allelic mutations cause 
atypical ADPKD with maturation and tracking defects, causing ADPKD but not causing 





5.5.3 Summary of DMFs 
Of the DMFs identified in this analysis, many are involved in signalling pathways or the 
structure of the cellular environment. These functions are expected in ADPKD, as signalling 
pathways including the roles of PKD1 and PKD2 have long been associated with the disease, 
as have physical characteristics such as increased fibrinogen, thick basement membranes, and 
increased collagen adhesion properties. 
 
Other DMFs, such as DCLRE1C and GET4, have roles in DNA damage and protein quality 
control. A review from Johnson and Collis [212] has highlighted the relationship between 
cellular stress in ciliopathies, and the role of the DNA damage repair (DDR) pathway. The 
breakdown of the DDR pathway could be postulated to cause the dysregulation of cellular 
control (thus leading to cellular proliferation), and investigation into the potential function of 
these genes in ADPKD requires further research. 
 
However, there are DMFs identified through this analysis for which the roles of the associated 
genes are within seemingly unrelated pathways. The genes CPLX1 and DAGLB are the most 
obvious examples of this, as they are both neuronal signalling genes. There is limited evidence 
to suggest that PC1 plays a role in the epithelial lining of the cerebral cortex of the brain, and 
mutation within the genomic neighbour of PKD1, TSC2, causes tuberous sclerosis complex 
disorder in which tumours form in the brain. However, given that these genes (CPLX1 and 
DAGLB) were identified as containing differential methylation in kidney tissue, completely 
isolated from brain tissue or spinal fluid, it is unlikely that this network of genes is at play here.  
 
 The most reasonable explanation for this is that these methylation patterns are arising from the 




these regions of the genome have transcriptional roles that have not been identified in the 
analyses performed here (neither the CPLX1 nor DAGLB-associated fragment contain 
transcription factor sequences nor enhancer elements). 
 
The most promising genes identified in this analysis were NAGLU and GET4, which 
demonstrate differential methylation and concomitant reduction of mRNA. An appropriate 
follow up on this data would be to investigate whether the relationship between these 
observations is correlated; i.e. whether the differential methylation of these fragments is 
sufficient to cause reduced gene expression, possibly by the use of DNMT inhibition. 
 
5.6 Global methylation in ADPKD cysts 
The single cysts in this analysis are derived from patient ADPKD D (as single cyst tissue was 
not available for the other samples). The tissue sample from this patient in the whole tissue 
analysis (ADPKD D III) has the lowest global median methylation value of all the tissue 
samples. Both ADPKD D III and ADPKD 05 had lower median methylation and slightly lower 
interquartile methylation ranges, which may indicate that the altered RRBS protocol had a bias 
in which fragments with high DNA methylation may not be as easy to amplify and sequence 
from low amounts of DNA such as that used in the individual cyst analysis. 
 
The ADPKD cyst libraries largely had fewer fragments with high methylation values, and 
subsequently had lower median methylation values (Fig. 4.7A). When each cyst sample was 
paired by common analysed fragments with the non-ADPKD sample (Fig. 4.10), the non-
ADPKD genome reflected the methylation profile of the cyst in question, which shows that it 
was a technical aspect of the sequencing process which has caused the fragments with lower 




fixed tissue, which may have contributed to the lower median methylation values. This is 
discussed further in Section 5.9.3. 
 
Unlike the above analysis on whole tissue, the individual cysts did not all demonstrate global 
hypomethylation when compared to the non-ADPKD sample. Five of the cysts demonstrate 
statistically significant hypermethylation. One cyst demonstrated hypomethylation (as seen in 
whole tissue) and the remaining two samples have median methylation equal to that of the non-
ADPKD sample. This pattern of DNA methylation changes is reflected in the different grouping 
of cyst libraries by the hierarchical clustering. 
 
The differences between individual cysts may reflect different tubules of origin, such as the 
proximal or distal tubule. If this analysis were to be repeated, it would be interesting to perform 
immunohistochemistry on additional sections of the same cyst wall, in order to determine if 
these differences reflect the presence of proximal or distal tubule epithelia. Other reasons for 
the differences in methylation may include the disease trajectory of independent cysts. 
 
5.7 PKD1 
In contrast to previous data on the DNA methylation of PKD1, which showed hypermethylation 
of the gene body [139], this study found no statistically significant differential methylation 
surrounding PKD1 in ADPKD, although there are some regions trending towards a difference. 
While the data does not fully span the 50 kb gene, there is a 31 kb region (exons 2 – 46) with 
RRBS coverage. 
 
There is not sufficient coverage at the promoter in our data to define its methylation status, 




non- and ADPKD tissue. Woo et al. report that within a portion of the gene body (exon 43), 
ADPKD is significantly hypermethylated. There was RRBS coverage flanking this exon, and 
the methylation profiles of these fragments, while not statistically significant, support the notion 
that ADPKD has increased DNA methylation at this region. 
 
There are fewer fragments in the ADPKD single cyst samples that cover the PKD1 region, but 
due to consistent methylation values between samples, several fragments were identified as 
being significantly methylated when comparing all cyst samples against all non-ADPKD tissue 
with ANOVA.  These data concur with the observation in whole tissue and with Woo et al.’s 
published data; ADPKD is hypermethylated at the 3’ end of the gene. 
 
While the data in the current study shows the same trend in DNA methylation of PKD1 as Woo 
et al., the expression of the gene does not. It was demonstrated by Woo et al. that the 
hypermethylation of the PKD1 gene body was correlated with the reduction of PKD1 
expression, through treating cell lines with demethylating agents to promote hypomethylation 
and a reduction in cyst formation, leading the authors to conclude that increased gene body 
methylation (within exon 43) reduces the expression of PKD1, sufficient to initiate cystogenesis 
in ADPKD. The relationship between PKD1 methylation and expression was demonstrated on 
cell lines including WT 9-12. However, these changes were not seen in ADPKD tissue in our 
analysis, with a trend of increased PKD1 expression in ADPKD. 
 
The disparity between results is puzzling, but not altogether surprising as there are conflicting 
data on the dosage of PKD1 in ADPKD in published literature (Table 1.1). Adult human kidney 
tissue typically has little-to-no PKD1 expression (PKD1 is required in fetal renal cells [213]), 




in the cytoplasm. However this is not always the case, with multiple papers reporting a 
significant minority of tissues sampled containing no increased PKD1 expression [6, 62]. 
 
One reason for the differences may simply be the samples used for gene expression. The initial 
PKD1 expression data were generated from whole tissue samples as in this analysis, and the 
data from Woo et al. suggest a wide range of expression was seen between these samples, 
similar to what was observed in our data (Fig. 3.10). Woo et al.’s subsequent analyses on DNA 
methylation were performed on transformed cell lines, which, as demonstrated in Section 4.2, 
appear to have an altered methylome when compared with samples isolated from fresh patient 
tissue. Additionally, the 5-aza-dC treatment, used as a demethylating agent, acts by reducing 
the activity of the DNMT1 enzyme, and thus does not specifically target the gene of interest 
[214]. Therefore, PKD1 will not have been the only gene influenced by demethylation and there 
is a huge number of genes which would have been influenced by DNMT inhibition to reduce 
cyst growth that were not investigated. 
 
While we agree with the previous data that shows there is hypermethylation in the gene body 
of PKD1, it is not yet clear whether this is having an effect on gene expression. As the current 
expression data in this study has only been generated from mRNA, further investigations of the 
protein using western blots may demonstrate complexities of PKD1 transcription and 
translation not seen by qPCR, such as whether the transcribed gene is functional. 
 
5.8 microRNA 
Analysis of the microRNA located within the PKD1 gene was performed as these genes are 
associated with CpG islands, and have the ability to work as post-translational regulators. Given 




methylation occurs within the gene, it was decided to investigate the three miRNA located 
within the gene promoter and body to determine if DNA methylation had any influence on their 
expression. 
 
It was observed that two of the genes (miR-1225-5p and miR-3180-5p) have little-to-no 
expression in the kidney, and therefore they were not altered by any epigenetic influences 
occurring in ADPKD.  
 
However, miR-4516 was found to be expressed in the kidney tissue of both non- and ADPKD 
samples. miR-4516 is found within intron 1 of PKD1, 2.6 kb from the TSS. The preliminary 
analysis of miR-4516 expression in ADPKD tissue showed that the expression varied widely 
between samples. While this did not provide statistical evidence to support the loss or gain of 
miR-4516 in ADPKD, it does appear that the gene is dysregulated. 
 
Currently there is little information on the function of this miRNA, with literature suggesting 
that the downregulation of this gene leads to the accumulation of fibronectin and thickening of 
extracellular matrix (by negatively regulating fibronectin 1 – FN1) in psoriasis [215, 216].  
Although psoriasis is an epidermal disorder, increased fibronectin and thickening ECM is 
typical of ADPKD cysts [217, 218]. While there is insufficient evidence currently to confirm 
that miR-4516 is influenced by PKD1 expression, or that this is consequential to the 





5.9 Experimental limitations 
5.9.1 Immortalised cell lines 
Human immortalised cell lines are the most readily available and renewable source of nucleic 
acids that can be used in the molecular analysis of ADPKD. Both of the cell lines used in this 
project, WT 9-7 and WT 9-12, have been studied in a multitude of ADPKD studies, including 
the only other analysis of DNA methylation in ADPKD [139, 219-222]. Therefore, they are an 
established and well characterised sample for which direct comparisons can be made across 
studies. 
 
However, these cell lines are immortalised with wild type simian adenovirus 40, which enables 
them to proliferate indefinitely. The integration of the virus into the cell has had a consequence 
on the methylation of the cell line, as demonstrated by the correlation coefficients between the 
cell lines and whole tissue (Section 4.2). Loghmann-Adham et al. demonstrated that WT 9-12 
cells grow twice as fast as their counterparts immortalised with a temperature sensitive virus 
[141]. Therefore, in this study we have identified that the immortalised cell lines have 
limitations on their application in the analysis of the methylome, and possibly other epigenetic 
studies in ADPKD.  
 
5.9.2 Limitations of whole tissue sections 
The first part of this study utilised tissue taken from whole cystic human kidney. Whole tissue 
ADPKD sections likely contain several cell types from cystic and interstitial tissue [223]. 
Additionally, it is difficult to determine from which region of the nephron a dissected tissue 
sample has originated from, because the kidney morphology becomes distorted due to the cystic 
overgrowth. Assumptions about the tubule of origin can be made from staining a tissue sample, 





Isolating tissue from individual cyst walls reduces the number of cell types and the amount of 
interstitial tissue in each sample, and the hope of generating RRBS libraries from this was that 
these would better illustrate similarities and differences between cysts. However, these walls 
were dissected with surgical scissors, and the selection was ‘blunt’ (as compared to laser 
dissection or similar techniques [224]) meaning that there is likely still neighbouring connective 
tissue in each wall sample, rather than pure epithelial cells. Additionally, it was not possible to 
determine exactly where in the kidney they originated from (i.e. cortex or medulla), due to the 
distorted nature of the cystic ADPKD kidney morphology. However, these samples can be said 
to be enriched for epithelial cyst wall cells. 
 
5.9.3 Formalin-fixed tissue provides experimental complications 
The individual cyst samples were generated from tissue which had been fixed in formalin for 
seven days prior to our access to the tissue. Although care was taken during DNA extraction to 
optimise the yield of DNA (Section 2.1.1), NBF treatment can significantly degrade DNA. This 
occurs due to cross-links formed by formaldehyde [225].  
 
It has been shown that leaving tissue in NBF for longer than 24 hours reduces the yield of DNA 
from cDNA [155]. It is possible that this study is assessing the ability to amplify from formalin 
fixed DNA, as the means of assessment was qPCR, and formalin is known to increase the 
proportion of enzyme inhibitors [226]. Given that the RRBS protocol requires PCR 
amplification, it may be that the amplification of DNA is inhibited, rather than a lack of 





Additionally, NBF-treated tissue yields largely fragmented DNA [227]. As shown in Appendix 
G, the cyst libraries typically had a skewed distribution of fragment lengths, predominantly 
featuring small fragments. This likely had an effect on the coverage of the aligned fragments 
across the methylome, which could in part explain why these libraries had lower coverage than 
other libraries in the analysis. 
 
Furthermore, NBF may cause the deamination of DNA, including 5-methylcytosine residues 
which deaminate to thymine in the presence of formalin-fixation at a higher rate than to uracil 
[228, 229]. Perhaps the deamination of these 5-methylcytosine residues reduces the ability of 
MspI to cleave the recognition site CCGG, leading in turn to reporting a higher proportion of 
unmethylated fragments. This hypothesis is supported by data produced in Chapter 4 
(Fig. 4.7A), which demonstrated that the amount of coverage in the RRBS libraries contributed 
to the median methylation value. 
 
It could be hypothesised that the fixation of the tissues had an impact on the methylation, as the 
cyst libraries largely had lower median methylation than other RRBS libraries. Yet, some of 
the samples from whole tissue also displayed lower median methylation (Fig. 4.7A). There are 
two factors which possibly contribute to this observation. The first is that these low-median 
samples are almost exclusively from patient ADPKD D. There is a small chance that this patient 
is truly, globally hypomethylated at a higher percentage than other individuals. The second and 
more significant factor is that these hypomethylated-median libraries were generated from a 
protocol using five times less input DNA. While there are other published protocols for 
generating RRBS libraries from low input DNA that generate ~4 million CpG reads [160, 161], 
this analysis suggests caution should be used when generating libraries from formalin-fixed 




5.9.4 Sample population differences 
The composition of environmental factors in each sample population will likely have an 
influence on the DNA methylation. To limit this, it is best to draw data from populations which 
have common backgrounds (such as age-matched samples). Unfortunately, the complication of 
nephrectomy is such that kidneys are rarely removed from patients, and thus there is a limited 
pool of available tissue for analysis.  
 
The most significant contributors to variation between populations are likely to be age and sex 
(outlined in Appendix A). All the samples in this analysis were within one decade, minimising 
the variation due to age. Unfortunately, the only non-ADPKD tissue available through the tissue 
bank was female cortical renal tissue, and our ADPKD samples are predominantly male. This 
creates a potential environment for bias in the analysis, as females have one X chromosome 
silenced through DNA methylation. While none of the DMFs identified in this study were 
sex-linked, the global methylation patterns between the two tissue groups were reassessed by 
eliminating sex-linked chromosomes from the overall comparison (Appendix G). No change in 
global methylation was seen in any of the tissue samples, and ADPKD tissue remained globally 
hypomethylated by 2%. Therefore we can be assured that any effects of X chromosome 
silencing did not influence this trend. 
 
5.9.5 Considering the medical history of patients 
A consideration when performing studies on the epigenetic landscape in human tissue is that 
these patients were exposed to environmental factors which may be influencing the epigenetic 
profile of individuals. A multitude of unique aspects such as diet, physical activity and other 
lifestyle factors contribute to the unique profile of an individual. As the ADPKD patients have 




to have been a factor modifying their epigenetic landscape [230]. While this would not alter the 
bioinformatic assessment of DNA methylation, understanding the clinical history of patient 
samples provides greater context for elucidating whether changes are likely to be involved in 
initiating or maintaining disease, or arise in response to cystogenesis. Unfortunately due to the 
anonymisation of tissue samples, the patients’ medical history is unavailable, and we can only 
speculate on what medical interventions they underwent prior to nephrectomy. 
 
Based on common practices in treating ADPKD [231, 232], it is plausible that the patients were 
on medications, likely for the long-term management of symptoms. Like all compounds, 
pharmaceuticals have the potential to cause epigenetic changes. Some of these epigenetic 
changes are the direct mechanism by which a medication works (such as HDAC inhibition 
negatively regulating Wnt signalling pathways at therapeutic levels [233]), however many more 
changes are the indirect result of pharmaceuticals, believed to often manifest as side effects 
[234]. 
 
According to clinical reviews, the most commonly used medications in ADPKD include statins, 
beta-blockers and ACE inhibitors, which are all used to combat cardiovascular-related 
symptoms such as hypertension [235]. There is limited observational evidence to speculate that 
statins and beta-blockers could initiate epigenetic changes in other conditions: beta-blockers 
can increase the risk of diabetes [236] which is known to have an epigenetic components [237], 
and statins cause gene expression alterations thought to arise from epigenetic changes [234, 
238]. However, whether this could result in epigenetic changes to the kidney tissue, or play a 
broader role in the epigenetics of all tissue, is uncertain. There are not sufficient data to 





5.9.6 Limitations of advanced-stage ADPKD tissue 
All of the ADPKD tissue and cell lines used in this research were derived from the kidneys of 
patients with end-stage renal disease. While this ensures that the tissue that was used in this 
analysis was (truly) cystic, the analysis might be less likely to be able to elucidate any changes 
required to initiate cystogenesis, as these changes may have occurred four or more decades 
earlier. Therefore, the differences between ADPKD and non-ADPKD tissue may be 
highlighting the differences between ‘healthy’ and dysregulated tissue from chronically ill 
patients. These could also include changes in molecular pathways that occur in response to the 
disease; a consequence of disease instead of a causative factor. 
 
An example of epigenetic changes occurring in response to disease has been recently 
investigated in a metastudy performed on patients with chronic kidney disease (CKD) by way 
of epigenome-wide association studies [239]. Of 19 CpG sites identified in the study as being 
significantly differentially methylated in CKD, five of these regions were associated with renal 
fibrosis in patients. This suggests that pathological changes to the kidney, such as the fibrosis 
observed in chronic kidney disease, is linked to epigenetic changes. However, a comparison of 
these data with the data generated in our ADPKD study has shown no overlap between the 
differentially methylated regions in this CKD paper and the DMFs identified in our analysis. 
This suggests that the data identified in our study is likely demonstrating changes which are 
specific to ADPKD and not as a result of CKD.  
 
It is possible that the differences in sequencing methodologies has also contributed to this lack 
of overlap. However, there is an overlap of the CKD paper data (generated from Illumina 450k) 




can be seen in genome-wide analyses, and the lack of overlap is more likely to be biological 
differences. 
 
Despite our data not fitting with the chronic kidney disease data, it is unlikely that the changes 
to DNA methylation seen in this study are directly contributing to the initiating of cyst growth, 
considering they are end-stage kidneys. However the results seen here may provide information 
about the molecular pathways modified in APDKD, providing potential new targets for 
therapeutic intervention. 
 
A way to identify cystogenesis-associated epigenetic changes could be to sample early-stage 
ADPKD epithelial cells. These can be isolated and characterised from urine, as humans shed 
renal epithelial cells via their urine [240, 241]. This methodology is not commonly employed 
in ADPKD and would need further validation. Additionally, current published protocols 
predominantly use SV40 viruses to immortalise cells [242]. In order to accurately assess DNA 
methylation changes in ADPKD this protocol would need to be altered to avoid viral effects on 
epigenetic changes as seen in the immortalised ADPKD cell lines used in this study. However, 
unlike nephrectomy, this technique is non-invasive and would provide access to cellular 
material from a wider range of ADPKD patients, including various ages and patients with 
milder disease (such as PKD2-related disease) who never reach ESRD and therefore never 
require nephrectomy. 
 
Other PKD models commonly used to study molecular changes associated with disease include 
pluripotent stem cell lines, knockdown and knockout cell lines [243]. However, these do not 




a patient, and therefore would have a limited application for studying the epigenetic landscape 
of ADPKD. 
 
5.10 Future Directions 
In the future it would be important to extend the research covered in this thesis, especially to 
include more tissue samples. Human ADPKD tissue is limited both because there is a small 
population with the disease, and secondly because tissue is only available when kidneys are 
removed – this only happens when the kidneys grow to such an extent that they cause 
unmanageable pain or impede the function of other organs. 
 
In addition to the expansion of the data set presented here, further analysis should be performed 
on the individual ADPKD cyst libraries, including the identification of differentially methylated 
fragments in each cyst library. This research was outside the bounds of the project presented 
here, but further work will be done to analyse whether fragments are consistently methylated 
in ADPKD cysts across the kidney, or whether heterogeneity plays a role in the DNA 
methylation of the ADPKD kidney. 
 
Further assessment into the expression of genes in the individual cyst samples would be useful. 
It is interesting that within the eight individual cyst samples, the global trend in methylation 
compared to non-ADPKD tissue was variable, demonstrating both hyper- and hypomethylation. 
This indicates that there is heterogeneity within the cysts of the ADPKD kidney, and has 
implications for both the process of cystogenesis and the response to potential epigenetic 
therapies. While qPCR of the DMF-associated genes could be performed, it may be more 




available for analysis, and that analysis to identify DMFs may bring forward a number of 
additional genes to analyse. 
 
Despite variation at the global level, there were also similarities between the whole tissue data 
and the single cyst data within DMFs, which suggests there are fundamental differences in the 
methylome of ADPKD. The expression of these DMF-associated genes should be followed up 
in cyst tissue, to further identify whether the methylation of these genes is linked to their 
expression. 
 
GET4 expression was found to be significantly reduced in ADPKD, which had a strong negative 
correlation with the methylation of the DMF in the gene body. Further research needs to be 
performed to validate whether this is a causal relationship, and additionally to identify if the 
gene plays a role in the cystogenesis of the kidney in ADPKD. Suggested experimental 
approaches include the treatment of primary cell lines with demethylating agents to measure 
the effects of methylation on the gene expression. 
 
5.11 Conclusion 
We have shown that the methylome of kidney tissue is hypomethylated in ADPKD patients, 
and we have identified 13 fragments with statistically significant methylation in these patients. 
Of these, at least one gene has a change in expression correlating with this methylation. We 
have found no significant differential methylation in the ADPKD-causing gene PKD1, although 
there was a trend towards hypermethylation at the 3’ end of the gene, which correlated with an 
increase of PKD1 expression by qPCR. We have found no significant changes in the expression 





We have also demonstrated that the ADPKD kidney is heterogenous with regards to DNA 
methylation, as illustrated by varying global methylation patterns across eight individual 
ADPKD cysts from a single patient. Furthermore, the cysts fall into two distinct, isolated 
clusters when performing unsupervised hierarchical clustering. We have confirmed that of the 
13 DMFs in whole tissue, eight of these are significantly differentially methylated in ADPKD 
single cyst tissue. 
 
DNA hypomethylation has not been previously reported in ADPKD, and there are currently no 
published data on the methylome of individual ADPKD cysts. This research provides new data 
on the methylation landscape of ADPKD tissue, and identifies two genes (NAGLU and GET4) 









Supplementary Table A.1: Clinical data from samples used in this analysis 
Due to anonymisation of donated tissue, there is limited information on the patient history of historical 
ADPKD tissue. Blanks left where information unavailable. PKD1 mutations are not typically 
investigated, thus there is only disease-causing mutant information on patient ADPKD D – as this patient 



















































































ADPKD ADPKD ADPKD ADPKD ADPKD ADPKD ADPKD ADPKD ADPKD 
PKD1 
mutation n/a n/a n/a 

























RRBS Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
Patient 
age§ 
53 51 55 52   60 60 56   
Patient 
sex 
F F F M   M M M F F 
Year 
collected 
2010 2009 2015 2005 2007 2008 2016 2016 2016 1999* 1999* 
qPCR Yes Yes Yes Yes Yes Yes Yes No Yes No No 
§ Patient age at time of nephrectomy 
^ NBF-treated prior to our access to tissue 





Preparation of RRBS libraries 
 
 
Supplementary Figure B.1: Semi-quantitative PCR gel 
Semi-quantitative PCR amplifications of the RRBS libraries prepared using n = 15 and n = 20 PCR 
cycles were loaded onto NuSieve agarose gel (Section 2.2.4) in pairs. Following gel electrophoresis, the 
gel was imaged under UV light. This gel is of RRBS libraries from cysts 5, 6, 7 and 8 (L = 1 kb ladder). 
The number of PCR cycles to amplify each sample is assessed by determining how much product is 
between 150 – 325 bp without non-specific amplification. All of these samples required 20 cycles of 








Supplementary Figure B.2: Measurement of 1 Kb 
ladder 
The ladder from one side of the gel was excised and 
imaged next to a ruler to measure the exact location 
of the 150 bp and 325 bp bands. The lower edge of 
the gel was lined up with the 17 cm mark on the ruler. 
The 150 bp band was at 14.05 cm, the 325 cm band 







Supplementary Figure B.3: Large-scale amplification gel 
Once the RRBS libraries were excised from the gel for DNA extraction (Section 2.2.6), the gel was 
pieced together and imaged under UV. This shows that the RRBS library was cut out from the gel, 
leaving the adaptor dimer band (~100 bp) intact. The smear of DNA product above and below the 
















Supplementary Table C.1: Sequencing submission from low-input libraries 
Libraries sent to Otago Genomics Facility (OGF) in 2016, sequenced across three lanes.  
Library Adaptor Average fragment 
size (bp) 
Conc. (nM) Volume (uL) Adaptor 
trimming 
ADPKD D 1 AD005 292 10 10 Yes 
ADPKD D 2 AD006 245 2.65 5 Yes 
ADPKD D 3 AD002 276 6.86 5 Yes 
ADPKD D 4 AD004 217 2.68 7  
ADPKD D 5 AD012 313 10 10 Yes 
ADPKD D 6 AD007 325 10 10  
ADPKD D 7 AD019 335 10 10 Yes 
ADPKD D 8 AD010 249 5.7 7 Yes 
ADPKD D I AD001 203 10 10 Yes 
ADPKD D II AD011 203 10 10 Yes 
ADPKD D III AD003 221 10 10 Yes 
ADPKD 05 AD016 239 10 10  
 
Supplementary Table C.2: Sequencing submission from cell lines 
Libraries sent to OGF in 2016, sequenced across two lanes alongside three other RRBS libraries. These 
libraries were prepared with Jackie Ludgate. 
Library Adaptor 
Average fragment 
size (bp) Conc. (nM) Volume (uL) 
WT 9-7 AD011 306 10 30 
WT 9-12 AD003 298 10 30 
 
Supplementary Table C.3: Sequencing submission from RRBS libraries generated in previous 
research 
Libraries sent to OGF in 2015, sequenced across three lanes alongside 10 other RRBS libraries. These 
libraries were prepared by Michael Bates [140]. 
Library Adaptor Average fragment size (bp) Conc. (nM) Volume (uL) 
ADPKD 07 AD004 324 10 25 
ADPKD 08 AD002 340 10 25 
Non-ADPKD E AD006 305 10 25 
Non-ADPKD G AD007 269 10 25 




RRBS data processing 
 
RRBS sequences were returned as fastq files which were processed for analysis in command 
line using DMAP programs and in RStudio. Below are examples of the code used to generate 
this data in command line. 
 
# Trim fragments and concatenate into single file 
cleanadaptors -I contam.fa -t 3 -T 3 -x 4 HNYL2BCXY-2046F-01-14-
1_S1_L001_R1_001.fastq > ADPKD05.fastq 
cleanadaptors -I contam.fa -t 3 -T 3 -x 4 HNYL2BCXY-2046F-01-14-
1_S1_L002_R1_001.fastq >> ADPKD05.fastq 
cleanadaptors -I contam.fa -t 3 -T 3 -x 4 HVJWYBCXY-2046F-01-14-
1_S1_L001_R1_001.fastq >> ADPKD05.fastq 
 
 
# Quality check 
fastqc -o qc ADPKD05.fastq 
 
# Bismark alignment 
bismark -n 1 GRCh37 ADPKD05.fastq 
 
# Merge non-ADPKD libraries to create a reference file 





# Generation of list of fragments 




diffmeth -F 2 -t 10 -g Homo_sapiens.GRCh37.dna.chromosome. -L 40,220 -z  
-R NonE.fastq -R NonG.fastq -R NonH.fastq -S ADPKD05.fastq -S ADPKD07.fastq -S 
ADPKD08.fastq -S ADPKDDIII.fastq > ANOVA.txt 
 
# Gene annotation 






The following are examples of the programs and commands used in RStudio to perform data 









Supplementary Table E.1: Primer sequences for qPCR 























































Publication of data derived from this 
thesis 
 
The following paper manuscript describes global DNA methylation as observed in ADPKD 
from whole tissue samples (derived from work in Chapter Three): 
 
Bowden, S. A., Rodger, E. J., Bates, M., Chatterjee, A., Eccles, M. R., & Stayner, C. (2018). 
Genome-Scale Single Nucleotide Resolution Analysis of DNA Methylation in Human 




Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterised by the 
formation of fluid-filled cysts in the kidney and end stage renal disease by the fourth or fifth 
decade of life. Mutations in the PKD1 gene account for 85% of all cases of ADPKD. No 
curative therapy exists for patients affected by this disease and an underexplored avenue for the 
treatment of ADPKD is the targeting of epigenetic changes that occur during cystogenesis. 
Limited data exists on alterations in DNA methylation that are associated with ADPKD. Given 
the similarities between cyst growth and neoplasia, and the fact that two DNA methylation 
inhibitors are already FDA-approved for the treatment of myelodysplastic syndrome, we 
hypothesized that global DNA methylation patterns in ADPKD would parallel that observed in 
neoplasia, and which may provide an opportunity to treat ADPKD with epigenetic inhibitors.  





Methods: We generated single nucleotide resolution methylomes of cortical kidney tissue from 
individuals with ADPKD, and from non-ADPKD kidney tissue, using reduced representation 
bisulfite sequencing (RRBS). Using quantitative reverse transcription polymerase chain 
reaction (qRT-PCR), we investigated expression of the PKD1 gene in both ADPKD and non-
ADPKD kidney.  
Results: We have shown that ADPKD-derived genomic DNA exhibits global hypomethylation 
when compared with non-ADPKD kidney, a pattern commonly observed in DNA methylation 
studies of tumour derived tissue. We have also identified thirteen discrete regions that are 
significantly differentially methylated in ADPKD compared to non-ADPKD, and eight of these 
are gene specific. The PKD1 gene shows an increase in methylation at the 3’ end of the gene 
body, but in contrast to previously published data, this is not associated with a decrease in PKD1 
mRNA expression.  
Conclusion: This genome-scale single nucleotide resolution analysis of DNA methylation in 
human polycystic kidneys suggests that DNA methylation differences at specific loci are 
associated with ADPKD. Further exploration into the significance of these preliminary results 
may shed light on the disease process, and potentially reveal new therapeutic possibilities. 
 
Background 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of 
inherited kidney disease, affecting 1-5 per 10,000 individuals[1]. ADPKD is characterised by 
the formation of fluid-filled cysts within the kidney, with renal function declining in the fourth 
or fifth decade of life, leading to end stage kidney disease. Extra-renal clinical features include 





A germline mutation in one copy of either the PKD1 or PKD2 gene causes ADPKD, with 85% 
of cases attributable to a mutation in PKD1. Polycystin-1 and -2, are the protein products of the 
PKD1 and PKD2 genes, respectively, and have been shown to interact at their C-terminal 
domains in renal tubule epithelia[2]. Both are transmembrane proteins, with Polycystin-2 able 
to act as a nonselective cation channel on the plasma and/or the endoplasmic reticulum 
membrane[3]. Polycystin-1 has a large extra-cellular N-terminal domain and on the primary 
cilia is postulated to act as a mechanosensor that responds to renal flow, subsequently regulating 
Ca2+ ion flow via Polycystin-2[4].  
 
Recent data investigating epigenetic modification during cystogenesis has suggested a potential 
role for histone modification[5,6] and/or DNA methylation[7,8] in modulating cyst formation. 
DNA methylation occurs at cytosine residues within CpG dinucleotides, and is catalyzed by 
DNA methyltransferases (DNMTs). Methylation at the promoter of a gene is frequently 
associated with a loss of gene expression, while methylation in the gene body, particularly at 
the 3’ end of the gene, correlates with active expression of that gene[9].  There are, however, 
many exceptions to this generalized observation[10-13].   
 
Aberrant DNA methylation patterns are associated with many types of cancer, and accordingly, 
several DNMT inhibitors are currently FDA-approved for the treatment of myelodysplastic 
syndrome. Given that cysts are effectively benign neoplasms[14], and ADPKD itself has been 
described as ‘neoplasia in disguise’[15], there may also exist parallels in global DNA 
methylation patterns that could be exploited therapeutically. A previous study by Woo et al.,[7] 
profiled DNA methylation patterns in ADPKD tissues using MIRA-seq (methylated-CpG 




derived DNA, including hypermethylation of the PKD1 gene body (but not the PKD1 gene 
promoter), correlating with a decrease in PKD1 mRNA levels.  
 
To address the hypothesis that global DNA methylation patterns in ADPKD parallels that 
observed in neoplasia, which may provide an opportunity to treat ADPKD with epigenetic 
inhibitors, we have undertaken RRBS (reduced representation bisulfite sequencing) analysis of 
tissues from both ADPKD and non-ADPKD kidneys in the first genome-scale single nucleotide 
resolution analysis of DNA methylation in human polycystic kidneys.  
 
Methods 
Collection and processing of tissues 
The three non-ADPKD cortical kidney tissues were collected from adults aged 50-60yrs by the 
Christchurch Cancer Society Tissue Bank following nephrectomy to remove a renal tumour. 
Wildtype tissue was sampled as far from the tumour site as possible, and appeared normal 
histologically. The ADPKD tissue samples were cortical samples taken from cystic regions of 
the kidney of male patients with ADPKD (aged 50-60yrs). Clinical data for these patients was 
not collected as these data were anonymised. However patients were on dialysis prior to 
nephrectomy, which was performed around the time of kidney transplantation. All procedures 
for collection of renal tissue was approved by the Otago Human Ethics Committee H15/110. 
 
Preparation and sequencing of RRBS libraries 
RRBS libraries of kidney tissue were prepared according to previously published methods [16-
19]. Briefly, genomic DNA was extracted from frozen tissue using the QIAamp DNA Mini Kit 
(Qiagen) with an extended 16 hour Proteinase K treatment at 56 °C. Genomic DNA was 




fragments were end-repaired, A-tailed and ligated to methylated adaptors (Illumina, San Diego, 
CA). Fragments were size selected (150 to 330 bp post-adaptor-ligation size) on 3% Nusieve 
agarose gels (Lonza, Basel, Switzerland) and bisulfite converted using the EZ DNA 
methylation kit (Zymo Research, Irvine, CA). Bisulfite converted libraries were amplified by 
PCR (16-18 cycles) and size-selected again to eliminate primer contamination. Libraries were 
quantified using the Qubit fluorometer (Life Technologies, Grand Island, NY) and quality 
assessed on the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) using the high 
sensitivity DNA chip according to the manufacturer’s instructions. RRBS libraries were 
sequenced on an Illumina HiSeq2500 with single-ended 100 bp reads. Base-calling was 
performed with Illumina Real Time Analyzer (RTA) software [17].  
 
Quality assessment, alignment and DNA methylation analysis 
Quality of the sequenced reads for each sample was assessed using the FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) program. Adaptor sequences and 
unmethylated CpG bases at the 3¢ end of the reads that were added during end-repair step were 
removed using our in-house cleanadaptors program [20]. The sequenced reads were aligned to 
the complete human reference genome GRCh37 with the Bismark v0.6.4 alignment tool [21], 
allowing for only one mismatch in the seed. The DMAP package [22] was used to generate 
MspI fragment-based methylomes and perform differential methylation analysis of the two 
groups. Only fragments that had at least 2 CpG sites and covered by 10 or more sequenced 
reads in all libraries were included in an F test (ANOVA) to test for significant methylation 
differences between non-ADPKD and ADPKD kidney tissue. We used a false discovery rate 
of <0.05 and fragments with an absolute methylation difference of ≥0.10 between tissue groups 





Generating single nucleotide resolution methylomes of ADPKD and non-ADPKD kidney 
Reduced representation bisulfite sequencing (RRBS) was used to generate DNA methylomes 
of renal cortex tissue from four ADPKD patients and three non-ADPKD kidneys. For these 
seven samples, a total of 243 million 100 bp sequencing reads were generated.  The sequenced 
reads were mapped to the GRCh37 human reference genome using Bismark [21], with unique 
alignment efficiency ranging from 54.2% to 68% (median=66.2%, Supplementary Table S1). 
The median bisulfite conversion rate was calculated to be >98%, assuming that the total 
quantified non-CpG methylation was due to inefficient bisulfite conversion (Supplementary 
Table S1). We determined the CpG DNA methylation (on a scale of 0 to 1) using MspI 
fragments (40-220 bp) as the unit of analysis. Size-selected MspI fragments were the input for 
RRBS sequencing libraries and we have previously described the utility of this approach for 
analysing genome-scale DNA methylation patterns in human tissues [19,22-24]. 
 
Gene enhancer and transcription factor binding prediction 
To identify DMFs overlapping predicted enhancer regions, the GeneHancer database of 
genome-wide enhancer-to-gene associations [25] was downloaded from the GeneCards website 
(https://genecards.weizmann.ac.il/geneloc/genehancer.xlsx) and converted to GRCh37 
coordinates using the UCSC genome browser Liftover tool (http://genome.ucsc.edu/cgi-
bin/hgLiftOver). BEDTools (v2.26.0) intersect was used to identify enhancer-to-gene 
associations that overlapped with the DMFs we identified in ADPKD. The UCSC table browser 
was used to retrieve details of predicted transcription factor binding sites from the ORegAnno 
database [26] that overlap with DMFs we identified in ADPKD. 
 
Gene expression analysis 




samples used for RRBS, as well as an additional ADPKD sample. RNA was extracted from 
frozen tissue using the miRNeasy mini kit (Qiagen), and cDNA was synthesized using the high-
capacity cDNA reverse transcription kit (Applied Biosystems) without RNase Inhibitor. The 
qPCR analysis was performed on cDNA using the SYBR Premix Ex Taq (Tli RNaseH Plus) 
kit (Takara) in a LightCycler 480 system. All qPCRs were performed in triplicate with PKD1 
primers designed to target the 3´ end of the cDNA, with primers targeting B2M and EEF1A1 as 
housekeeping genes. Data analysis was carried out using the software qbase+ to determine the 
relative expression of PKD1 in ADPKD compared to non-ADPKD tissue. 
 
Results 
ADPKD shows global hypomethylation compared to non-ADPKD kidneys  
We compared global methylation patterns between the ADPKD and non-ADPKD kidneys. For 
this comparison, we required that each fragment fulfilled the coverage criteria of 10 or more 
reads and ≥ 2 CpG sites in each fragment) in both analysed groups. Subsequently referred to as 
“common analysed fragments”, there were 345,711 fragments (336,121 from autosomes and 
9590 from sex chromosomes) that contained a total of  1,785,585 CpG sites. The distribution 
of global methylation patterns revealed a bimodal distribution in both non-ADPKD and 
ADPKD samples (Supplementary Fig. S1). This observation is consistent with RRBS 
methylomes observed in somatic cells [23,24]. 
 
The global methylation profiles of the common analysed fragments showed slight, yet 
significant, hypomethylation in ADPKD compared to non-ADPKD kidney (Wilcoxon rank 
sum test, P-value < 2.2e-16, median methylation = 0.76 and 0.78 in ADPKD and non-ADPKD 
kidney respectively). We wanted to determine whether the hypomethylated fragments were 




individual genomic elements: gene promoters (-5kb to +1 kb from TSS), introns, exons, intron-
exon boundaries and intergenic regions (Figure 1A and Supplementary Table S2). We also 
performed global analysis on CpG island (CGI) features: CGI cores (contains the core 
CpG island), CGI shores (flanking 2 kb either side of the CGI core), CGI shelfs (flanking 2 kb 
either side of the CGI shore) and open sea (isolated CpGs in the genome) (Figure 1B and 
Supplementary Table S3). Hypomethylation of ADPKD was observed in all these genomic 
elements and CGI features (~2%), but more so in exons (3%) and to a lesser extent in fragments 
overlapping promoters (1%), intron/exon boundaries (0.3%) and CGI cores (0.8%). 
 
Region-specific differential methylation in ADPKD 
Differential methylation analysis was used to determine region-specific methylation differences 
between ADPKD and non-ADPKD kidney tissue. RRBS MspI fragments were used as the unit 
of analysis as previously described [19,23,24]. An ANOVA test followed by corrrection for 
false discovery rate (FDR <0.05) and the requirement for an absolute difference between  
kidney and ADPKD methylation of ≥0.10 identified 13 significantly differentially  methylated  
fragments  (DMFs)  among  the 345,711 common analysed fragments (Figure 2A, Table 1). Of 
the DMFs, 62% were hypomethylated in ADPKD  compared  to non-ADPKD kidney  (eight  
hypomethylated;  five hypermethylated). In relation to genomic features, two DMFs overlapped 
with gene promoters (-5kb to +1 kb from the transcription start site, TSS), six overlapped with 
gene bodies (five in introns and one in an intron/exon boundary) and five were intergenic (>5kb 
upstream of any gene). In comparison to the common analysed fragments (Figure 2B), there 
was an enrichment of DMFs overlapping with intergenic regions and intron/exon boundaries 
(Figure 2C). The two genes containing promoter DMFs were: NAGLU (which encodes an 
alpha-N-acetylglucosaminidase enzyme) and EFCAB4B (a calcium channel regulator; Figure 




vesicle exocytosis) GET4 (a part of the BAG6/BAT3 cytosolic protein quality control complex), 
DAGLB (a diacylglycerol lipase enzyme), KDELR2 (a receptor required for retention of 
proteins in the endoplasmic reticulum), DCLRE1C (a DNA cross-link repair enzyme), and 
TMPRSS6 (a type II transmembrane serine proteinase; Figure 2D, Table 1). Some of the DMFs, 
including two that were intergenic, overlapped predicted gene enhancer regions 
(Supplementary Table S4) and transcription factor binding sites (Supplementary Table S5).  
 
The methylation landscape of PKD1 in ADPKD 
PKD1 is a large gene (47.2 kb in length with 46 exons and 47 introns) that plays a central role 
in the pathogenesis of AKPKD. To our knowledge there is currently no single nucleotide 
resolution DNA methylation data available for the whole PKD1 gene in ADPKD. Therefore, 
here we have particularly focused on characterizing the methylation status of this gene. For the 
PKD1 gene, we obtained high quality methylation information for 68 RRBS fragments 
containing 374 CpG sites (Supplementary Table S6). Our RRBS libraries did not have sufficient 
sequencing read coverage upstream of the TSS, with the exception of one 67 bp fragment 
containing 9 CpGs (3.6 kb from TSS) that was fully methylated in both ADPKD and non-
ADPKD but in contrast, exon 1 and part of intron 1 was almost fully unmethylated. The gene 
body of PKD1 was largely fully methylated in both non-ADPKD and ADPKD kidney tissue 
(Figure 3A and Supplementary Table S6). These findings are consistent with the pattern 
observed in RRBS libraries of kidney tissue and kidney epithelial cells from the ENCODE 
project (ENCSR938TEC) [27]. There were no statistically significant DMFs in PKD1 using a 
FDR adjusted P-value <0.05, but with a nominal raw P-value threshold of <0.05 from the 
ANOVA, the ADPKD tissue had ten fragments in PKD1 with methylation differences greater 
than 0.10 compared to non-ADPKD kidney (Figure 3B and Supplementary Table S6). Three of 




less methylated in ADPKD (14-44% difference in methylation) compared to non-ADPKD 
kidney. The other six fragments in intron 32, overlapping introns 40-41 and exons 41-42, and 
the intron 45/exon 46 junction at the 3’ end of the PKD1 gene body were more methylated in 
ADPKD (Figure 3B and Supplementary Table S6). One of the intron one fragments overlapped 
a predicted binding site for the transcriptional repressor CTCF (Supplementary Figure S2). Five 
of the 3´ fragments overlapped a predicted enhancer (Genehancer ID: GH16H002086, gene-
enhancer score = 12.2; Supplementary Table S6) and four of these fragments overlapped a 
predicted binding site for POLR2A, which potentially regulates transcription of PKD1 
(Supplementary Figure S2).  
 
A previous study had correlated an increase in PKD1 gene body methylation with a decrease in 
PKD1 mRNA expression in human ADPKD kidney[7]. We investigated the mRNA expression 
level of PKD1 in five ADPKD kidney samples, (including the four samples for which we had 
RRBS data) and compared this with the three non-ADPKD kidney samples. None of the 
ADPKD samples showed a decrease in PKD1 expression when compared with non-ADPKD 
kidney, with most showing a higher level of PKD1 mRNA. Overall the PKD1 gene had a 
significant 2-fold higher expression (P-value = 0.036) in ADPKD compared to non-ADPKD 
kidney (Figure 3C). Notably, the level of methylation in three of the 3´ fragments was 
significantly correlated (P-value < 0.05) with PKD1 expression (Supplementary Table S7).  
 
Discussion 
By generating and analysing single nucleotide resolution methylomes of cortical kidney tissue 
from individuals with autosomal dominant polycystic kidney disease (ADPKD) and from non-
ADPKD kidney tissue, we have shown that ADPKD exhibits global hypomethylation when 




PKD1 gene body, which is associated with a significant increase in PKD1 mRNA expression. 
In addition, thirteen loci show statistically significant differential gain or loss of methylation in 
ADPKD renal tissue. 
 
In cancer, global hypomethylation and site-specific gain of DNA methylation is observed [28]. 
Our results indicate that the methylation landscape of ADPKD compared to normal kidney is 
more likely to resemble the pattern observed in human cancers. However, the specific method 
used for global methylation profiling has implications in interpreting these results. We have 
used RRBS in this study, which enriches for functionally important CpG-rich regions of the 
genome but does not include repetitive elements at sufficient coverage. Repetitive elements are 
generally silenced by high amounts of DNA methylation. In cancers, several types of these 
repeat elements tend to lose methylation marks, leading to global hypomethylation [9]. Based 
on our data, it is plausible that if whole genome methylation were analysed, the degree of 
hypomethylation is likely to be even more pronounced in ADPKD samples compared to normal 
kidney tissue. 
 
In contrast to these RRBS data, genome–wide methylation profiling of ADPKD tissues by Woo 
et al.,[7] using MIRA seq, indicated a global hypermethylation, with only 9% of the ADPKD 
genome being hypomethylated. In agreement with the RRBS data, they also observed 
hypermethylation of the PKD1 gene body.  However, Woo et al have correlated this PKD1 
hypermethylation with a decrease in PKD1 gene expression levels, whereas our PKD1 gene 
expression analysis did not indicate a loss of PKD1 expression in the ADPKD tissues, with all 
ADPKD samples showing the same or higher mRNA levels when compared with non-ADPKD 
renal tissue. Overall, there was a 2-fold higher expression of PKD1 in the ADPKD samples 




an increase in PKD1 mRNA and protein expression in ADPKD kidney.[29-33] In addition, the 
level of PKD1 expression we observed in each ADPKD sample significantly correlated with 
the extent of DNA methylation in several fragments at the 3’ end of the PKD1 gene body 
(Supplementary Table S7). 
 
The difference in the findings of our study and Woo et al. could be largely explained by the 
platform used for profiling methylation patterns. There are at least twenty different techniques 
that have been developed to interrogate genome-wide DNA methylation patterns[34], which 
provide snapshots of the genome based on their design. The most commonly-used of these 
include HumanMethylation450 BeadChip (450K) DNA methylation profiling, enrichment-
based methods include Methylation-dependent Immunoprecipitation followed by sequencing 
(MeDIP-Seq) and MIRA-seq[35], reduced representation bisulfite sequencing (RRBS) and 
whole genome bisulfite sequencing (WGBS).  While WGBS potentially allows investigation 
of every CpG site in the genome, cost and data management considerations have advanced the 
use of alternative methods. RRBS is an alternative to WGBS, that through the use of a 
methylation insensitive restriction digest and size selection process, enriches for CpG sites, 
CpG islands (~ 30-fold for human) and gene promoters and gene bodies[36]. The 450K 
BeadChip approach is the most popular method for genome-wide DNA methylation due to its 
low cost and ease of data analysis. However 450K arrays allow investigation of only 1.7% of 
the CpG sites in the genome, one tenth the sites examined using RRBS.  Enrichment-based 
methods have a number of limitations and do not allow investigation of single CpG sites, with 
a lower accuracy rate when compared to RRBS and WGBS[37]. 
 
Woo et al. used MIRA (methylated-CpG island recovery assay), which exploits the affinity of 




proteins form a complex and have higher affinity to bind to methylated DNA (in the CpG 
context). The binding of this complex is dependent on the CpG density of the genomic locus 
[38]. These bound DNA fragments (enriched for CpG-methylated DNA) are sequenced 
followed by analysis of methylation. On the other hand, RRBS is based on MspI digestion 
followed by massively parallel sequencing to provide a genome-wide methylation map [20]. A 
recent study of B-cell subsets using MIRA-Seq demonstrated that the majority of methylation 
peaks are present in intergenic and intronic regions, and are less frequent in CpG islands [39], 
while RRBS highly enriches for CpG island fragments. We hypothesise that the difference in 
these two approaches results in analysis of different CpGs and therefore dissimilar differential 
methylation patterns. The two platforms also substantially differ in their CpG coverage. For 
example, Woo et al obtained 1 million distinct CpG sites (per million sequence reads) for the 
pooled non-ADPKD tissue, and 0.7 million unique CpG sites for the three ADPKD tissues. In 
contrast, we analysed 1,525,770 unique CpG sites in both groups using RRBS.  MIRA is based 
on the principle of affinity and enrichment, and a limitation of this approach is that they do not 
allow investigation of single CpG sites, and the efficiency of the methylation calls is affected 
by the CpG density of the genomic locus [40]. Moreover, they are more prone to error if the 
samples have copy number variation. Large-scale studies have demonstrated that enrichment-
based methods have lower accuracy compared to RRBS and Whole Genome Bisulfite 
Sequencing (WGBS) [37,41]. 
 
Another factor that may explain differences found between these two studies is that of tissue 
heterogeneity. While both Woo et al.,[7] and the current study have sampled cystic tissues from 
the renal cortex of ADPKD patients, there is likely to be tissue variation between samples. In 
addition, the potential for different cell types to be present within or between samples could 




also exists that the DNA methylation differences noted between ADPKD and non-ADPKD 
kidney are related to changes associated with end-stage kidney disease, rather than cystic 
growth.  A recent study by Chu et al., 2017[42], identified DNA methylation changes associated 
with chronic kidney disease (CKD) in two large cohorts of CKD patients.  However, none of 
the 243 eGFR-associated CpGs identified overlap with our DMFs, leading us to conclude that 
the DNA methylation changes uncovered in the current study are not related to CKD. A further 
limitation in this study is the small number of samples analysed, which limits the statistical 
power for detecting significant differences between the two groups. Future studies using a 
higher number of ADPKD samples will provide further insights about the differential 
methylation landscape in this disease. However, this first genome-scale single nucleotide 
resolution analysis of DNA methylation in human polycystic kidney using RRBS, has revealed 
a number of loci that are epigenetically altered in cystic tissue, and further elucidation of the 
potential role these play in cystogenesis will be the subject of future studies. 
 
Conclusions 
Methylation profiles of ADPKD kidney using RRBS showed global hypomethylation in 
ADPKD compared to non-ADPKD kidney. This is in contrast to previously published work but 
is consistent with the observed similarities between ADPKD and neoplasia. Thirteen 
significantly differentially  methylated  fragments were identified, eight of which are associated 
with a specific gene. In addition, ten fragments in the PKD1 gene showed differences in 
methylation between ADPKD and non-ADPKD kidney. However, none of the ADPKD tissue 
samples showed a decrease in PKD1 expression when compared with non-ADPKD kidney, 
with most showing a higher level of PKD1 mRNA. These data suggest that DNA methylation 
differences are associated with ADPKD and further exploration into the significance of these 
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Figure 1: Global DNA methylation patterns of different genomic and CpG island features in 
ADPKD. DMAP software was used to generate MspI fragment-based methylomes from the 
renal cortex of non-ADPKD (n=3, shown in blue) and ADPKD kidney (n=4, shown in red). A. 
In all common analysed fragments (n=345,711), the median methylation in ADPKD (0.76) was 
significantly lower (Wilcoxon rank sum test, P-value < 2.2e-16) than non-ADPKD kidney (0.78) 
and this trend was also observed in the different genomic features: gene promoters, introns, 
exons and intergenic regions. B. The median methylation in ADPKD was also lower in all the 
different CpG island (CGI) features: CGI core (contains the core CpG island), CGI shore 
(flanking 2 kb either side of the CGI core), CGI shelf (flanking 2 kb either side of the CGI shore) 
and open sea (isolated CpGs in the genome). Boxplots show the distribution of methylation: 







Figure 2: Differentially methylated fragments identified in ADPKD. DMAP software was used 
to determine region-specific methylation differences between non-ADPKD (n=3) and ADPKD 
(n=4) kidney using the MspI fragments as the unit of analysis. An ANOVA test followed by 
correction for false discovery rate (FDR<0.05) and inclusion of fragments with a methylation 
difference ≥10%. was used to identify significantly differentially methylated  fragments 
(DMFs). A. Methylation of each of the 13 DMFs is plotted on a heatmap from 0 (dark blue) to 




genomic distribution of the 13 DMFs. D. Scatter dot plots of the 8 DMFs overlapping promoter 




Figure 3: The methylation profile of the PKD1 gene in ADPKD compared to non-ADPKD 
kidney. A. UCSC genome browser view of RRBS fragments (in black track; DMFs shown with 
red asterisk) overlapping the PKD1 gene (blue track), CpG islands (green track) and ENCODE 
transcription factor binding sites (grey/black track). The MspI fragment-based methylomes 
from renal cortex of non-ADPKD (n=3, blue line) and ADPKD kidney (n=4, red line) had 68 
fragments (black bars, median length = 86 bp) across the PKD1 gene. B. Using a nominal raw 
P-value threshold of <0.05 from the ANOVA, the ADPKD tissue had ten fragments in PKD1 
with methylation differences greater than 10% compared to non-ADPKD kidney (loci indicated 
in panel A with red asterisks).  C. PKD1 gene expression in ADPKD was significantly higher 
(Mann Whitney U test, P-value < 0.05) than non-ADPKD kidney. An additional ADPKD 
sample to those analysed by RRBS was included in the expression analysis (n=5). Bars show 




Table 1. Differentially methylated fragments identified in ADPKD 
Chr 
Fragment  








1 Closest protein-coding gene and function 
2 771624 – 771728 0.049 0.44 0.79 0.34 -94kb from TMEM18 
4 793929 – 794143  0.034 1.00 0.82 -0.18 
CPLX1 (intron 2) 
Cytoplasmic vesicle 
exocytosis 
7 922176 – 922249 0.003 0.33 0.85 0.52 
GET4 (intron 1) 3 
Cytosolic protein quality 
control 
7 6495310 – 6495378 0.034 0.37 0.59 0.22 
DAGLB (intron 1) 
Diacylgylcerol lipase 
enzyme 
7 6511106 – 6511153  <1.79E-17 1.00 0.90 -0.10 
KDELR2 (intron 2) 
Protein retention in the 
ER 
DAGLB (intron 1) 
Diacylgylcerol lipase 
enzyme 
9 130768316 – 130768366  0.038 0.56 0.13 -0.43 -26 kb from FAM102A
2, 3 
10 14979087 – 14979136  <1.79E-17 0.00 1.00 1.00 
DCLRE1C (intron 4) 
DNA crosslink repair 
12 3862528 – 3862582 0.035 0.25 0.08 -0.17 
EFCAB4B (promoter) 3 
Calcium channel regulator 
17 40683608 – 40683711  0.048 0.57 0.34 -0.23 
NAGLU (promoter) 3 
Alpha-N-
acetylglucosaminidase 
18 10271529 – 10271568 <1.79E-17 1.00 0.80 -0.2 -183kb from APCDD1 
19 789109 – 789181 0.034 0.71 0.35 -0.36 -8kb from PTBP12, 3 
20 2513933 – 2513980 1.79E-17 0.90 0.67 -0.23 -9kb from ZNF343 
22 37499386 – 37499523  0.048 0.25 0.43 0.18 




1 Methdiff = average methylation difference between non-ADPKD and ADPKD kidney tissue (a negative value 
indicates hypomethylation in ADPKD tissue compared to non-ADPKD). 
2 Fragment overlaps a transcription factor binding site for this gene, as predicted by OregAnno analysis. 






Supplementary Figure G.1: Median global methylation of ADPKD and non-ADPKD tissue 
excluding sample ADPKD D III 
Sample ADPKD D III was excluded from the global analysis to confirm that the lower median 
methylation of this fragment was not contributing to the pattern of hypomethylation seen in ADPKD. 
Non-ADPKD n = 3 (blue), ADPKD n = 3 (red). p < 2.2E-16. 
 
Supplementary Table G.1: Correlation between DMF methylation and PKD1 expression in 
ADPKD and non-ADPKD tissue 
Correlation calculated with Spearman’s correlation: * = p < 0.05, ** = p < 0.01. XY pairs refers to the 
number of comparisons between DMF methylation and PKD1 expression in each Spearman’s 
correlation calculation at each coordinate. 
 
Chromosome coordinates: r (p): XY pairs: 
16:2140121-2140224 0.9286 (**) 7 
16:2141559-2141709 1 (**) 6 
16:2141710-2141753 0.8214 (*) 7 
16:2141754-2141820 0.5714 7 
16:2141821-2141911 0.9 5 
16:2147611-2147671 0.8857 (*) 6 
16:2165619-2165775 -0.6 4 
16:2174437-2174483 -0.9643 (**) 7 
16:2174683-2174753 -0.7714 6 

















   
   
   
   




Supplementary Figure G.2: Distribution of fragment sizes in RRBS libraries 
Depiction of the distribution of RRBS fragment lengths. Fragments are no shorter than 40 bp and no 
greater than 220 bp. Libraries generated from 0.5 µg of DNA do not have a distinct peak at 140 bp 












































































































































































































































































































































































































































































































































































































































































Supplementary Figure G.3: Median methylome analysis at CpG islands 
The median methylation of the non-ADPKD reference sample (blue) and ADPKD D (red) in relation to 
CpG islands. ADPKD was significantly hypomethylated at all regions, therefore the reason for global 




















Correlation of RRBS libraries 
Supplementary Table H.1: Pearson’s correlation coefficient between all 19 RRBS libraries 









Supplementary Figure I.1: qPCR of whole tissue DMF identified genes 
Eight genes associated with DMFs were investigated with qPCR in whole tissue from renal samples. 
n(non-ADPKD) = 3, n (ADPKD) = 5. Only GET4 and NAGLU had significant differential expression 
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